Dulaglutide and cardiovascular outcomes in type 2 diab randomised placebo-controlled trial

Lancet, The

394, 121-130

DOI: 10.1016/s0140-6736(19)31149-3

Citation Report

#	Article	IF	Citations
3	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes and Endocrinology,the, 2019, 7, 776-785.	5.5	961
4	Type 2 diabetes: Why should diabetologists and cardiologists work more closely together?. Diabetes and Metabolism, 2019, 45, 501-504.	1.4	8
5	What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?. Diabetes Therapy, 2019, 10, 1719-1731.	1.2	5
6	Incretin Hormones: The Link between Glycemic Index and Cardiometabolic Diseases. Nutrients, 2019, 11, 1878.	1.7	14
7	Treatment of Type 2 Diabetes by Patient Profile in the Clinical Practice of Endocrinology in Spain: Delphi Study Results from the Think Twice Program. Diabetes Therapy, 2019, 10, 1893-1907.	1.2	2
8	GLPâ€1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated metaâ€analysis including the REWIND and PIONEER 6 trials. Diabetes, Obesity and Metabolism, 2019, 21, 2576-2580.	2.2	104
10	Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care, 2019, 42, 2098-2107.	4.3	37
11	Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features. Clinical Drug Investigation, 2019, 39, 805-819.	1.1	47
12	Review of glucagonâ€like peptideâ€1 receptor agonists for the treatment of type 2 diabetes mellitus in patients with chronic kidney disease and their renal effects. Journal of Diabetes, 2019, 11, 938-948.	0.8	30
13	Clinical aspects of heart failure in individuals with diabetes. Diabetologia, 2019, 62, 1529-1538.	2.9	14
14	Debate on Insulin vs Non-insulin Use in the Hospital Settingâ€"Is It Time to Revise the Guidelines for the Management of Inpatient Diabetes?. Current Diabetes Reports, 2019, 19, 65.	1.7	43
15	T2DM treatment trial results. Nature Reviews Endocrinology, 2019, 15, 499-499.	4.3	0
16	Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin. Metabolism: Clinical and Experimental, 2019, 98, 104-111.	1.5	18
17	Diabetes news. Journal of Diabetes, 2019, 11, 781-785.	0.8	0
18	Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction. European Heart Journal, 2020, 41, 882-889.	1.0	25
19	Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1â€"2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis. Diabetes Therapy, 2019, 10, 2183-2199.	1.2	28
20	Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis. Diabetes Therapy, 2019, 10, 2321-2330.	1.2	6
21	Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. American Journal of Nephrology, 2019, 50, 345-356.	1.4	127

#	Article	IF	Citations
22	Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!. Metabolism: Clinical and Experimental, 2019, 101, 154001.	1.5	67
25	Do GLP-1 Receptor Agonists Care if You Have Heart Failure?. Circulation, 2019, 140, 1623-1625.	1.6	1
26	A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. American Journal of Medicine, 2019, 132, S13-S20.	0.6	1
30	Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. Cardiovascular Diabetology, 2019, 18, 138.	2.7	48
31	Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. Diabetes Therapy, 2019, 10, 1733-1752.	1.2	47
32	Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes. Advances in Therapy, 2019, 36, 2567-2586.	1.3	12
33	Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?. Metabolism: Clinical and Experimental, 2019, 100, 153960.	1.5	16
34	The right place for Sulphonylureas today: Part of â€˜Review the Series: Implications of recent CVOTs in Type 2 diabetes mellitusâ€™. Diabetes Research and Clinical Practice, 2019, 157, 107836.	1.1	23
35	Glucose-lowering drugs and heart failure: implications of recent cardiovascular outcome trials in type 2 diabetes. Diabetes Research and Clinical Practice, 2019, 157, 107835.	1.1	8
36	GLP-1 receptor agonists and cardiovascular outcomes: an updated synthesis. Lancet Diabetes and Endocrinology,the, 2019, 7, 741-743.	5.5	9
37	Association of Antihyperglycemic Therapy with Risk of Atrial Fibrillation and Stroke in Diabetic Patients. Medicina (Lithuania), 2019, 55, 592.	0.8	14
38	Suitable Use of Injectable Agents to Overcome Hypoglycemia Risk, Barriers, and Clinical Inertia in Community-Dwelling Older Adults with Type 2 Diabetes Mellitus. Drugs and Aging, 2019, 36, 1083-1096.	1.3	4
39	Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes. Postgraduate Medicine, 2019, 131, 555-565.	0.9	10
40	Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study. Cardiovascular Diabetology, 2019, 18, 120.	2.7	47
41	Review of multimodal treatment for type 2 diabetes: combining metabolic surgery and pharmacotherapy. Therapeutic Advances in Endocrinology and Metabolism, 2019, 10, 204201881987540.	1.4	23
42	Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK. Diabetes Therapy, 2019, 10, 2131-2137.	1.2	20
43	Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures. Cardiovascular Diabetology, 2019, 18, 130.	2.7	8
44	Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failureâ€“Related Outcomes. Circulation, 2019, 140, 1613-1622.	1.6	58

#	Article	IF	Citations
45	GLP1R agonists: primary cardiovascular prevention and oral administration. Nature Reviews Cardiology, 2019, 16, 453-453.	6.1	1
46	Is it time to REWIND the cardiorenal clock in diabetes?. Lancet, The, 2019, 394, 95-97.	6.3	1
47	Type 2 Diabetes. Annals of Internal Medicine, 2019, 171, ITC65-ITC80.	2.0	46
49	Treatment of Patients with Heart failure and Type 2 Diabetes: a review of the literature. Italian Journal of Medicine, 2019, 13, 205-224.	0.2	0
50	Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. BMJ Open Diabetes Research and Care, 2019, 7, e000705.	1.2	26
51	Benefits and harms of intensive glycemic control in patients with type 2 diabetes. BMJ: British Medical Journal, 2019, 367, l5887.	2.4	84
53	Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2019, 381, 2075-2077.	13.9	9
54	A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes. American Journal of Cardiology, 2019, 124, S12-S19.	0.7	15
55	Therapy of Type 2 Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, S73-S92.	0.6	38
56	Position Paper on the Diagnosis and Treatment of Peripheral Arterial Disease (PAD) in People with Diabetes Mellitus. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, S105-S113.	0.6	9
57	Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?. Clinical Diabetes, 2019, 37, 316-337.	1.2	11
58	Risk factor reduction in type 2 diabetes demands a multifactorial approach. European Journal of Preventive Cardiology, 2019, 26, 81-91.	0.8	13
59	Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases. European Journal of Preventive Cardiology, 2019, 26, 73-80.	0.8	56
60	The Changing Landscape of Pharmacotherapy for Diabetes Mellitus: A Review of Cardiovascular Outcomes. International Journal of Molecular Sciences, 2019, 20, 5853.	1.8	11
61	Trends in Cause-Specific Outcomes Among Individuals With Type 2 Diabetes and Heart Failure in the United Kingdom, 1998-2017. JAMA Network Open, 2019, 2, e1916447.	2.8	4
62	Injectable Therapy for Diabetes Mellitus: Glucagon-Like Peptide-1 Receptor Agonist. Journal of Korean Diabetes, 2019, 20, 149.	0.1	0
63	Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient!. Archives of Medical Science, 2019, 15, 1357-1364.	0.4	31
64	Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2019, Volume 12, 2515-2529.	1.1	20

#	Article	IF	Citations
65	Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration. Current Diabetes Reports, 2019, 19, 157.	1.7	7
66	Review of cardiovascular outcomes trials of sodiumâ€“glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Current Opinion in Cardiology, 2019, 34, 687-692.	0.8	24
68	Cardioprotective diabetes drugs: what cardiologists need to know. Cardiovascular Endocrinology and Metabolism, 2019, 8, 96-105.	0.5	11
69	Lessons From a Diabetes Clinic: Achieving Glycemic Goals and Clinical Use of Antidiabetic Agents in Patients With Type 2 Diabetes. Clinical Diabetes, 2020, 38, 248-255.	1.2	7
70	Mechanisms by Which Glucagon-Like-Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors Reduce CardiovascularÂRisk in Adults With Type 2 Diabetes Mellitus. Canadian Journal of Diabetes, 2020, 44, 93-102.	0.4	35
71	Weighing Coronary Revascularization Options in Patients With Type 2 Diabetes Mellitus. Canadian Journal of Diabetes, 2020, 44, 78-85.	0.4	5
72	Glucagon-Like Peptide-1 Receptor Agonists in Adult Patients With Type 2 Diabetes: Review of Cardiovascular Outcome Trials. Canadian Journal of Diabetes, 2020, 44, 68-77.	0.4	15
73	Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin. Journal of Medical Economics, 2020, 23, 193-203.	1.0	17
74	Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocrine Reviews, 2020, 41, 66-117.	8.9	134
75	Efficacy of newer agents in the glycaemic management of patients with type 2 diabetes. Current Medical Research and Opinion, 2020, 36, 209-211.	0.9	3
76	Diabetes drugs and stroke risk: Intensive versus conventional glucoseâ€lowering strategies, and implications of recent cardiovascular outcome trials. Diabetes, Obesity and Metabolism, 2020, 22, 6-15.	2.2	36
77	From pump to sink: The hydraulic connection of type 2 diabetes. Diabetes Research and Clinical Practice, 2020, 159, 107772.	1.1	0
78	Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist. Diabetes Technology and Therapeutics, 2020, 22, 10-18.	2.4	98
79	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2020, 41, 255-323.	1.0	2,811
80	Evidenceâ€based comparison of glucagonâ€like peptide receptor agonists and sodiumâ€“glucose cotransporterÂ2 inhibitors. Journal of Diabetes Investigation, 2020, 11, 17-19.	1.1	3
81	Trend 2010â€“2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy. Acta Diabetologica, 2020, 57, 367-375.	1.2	20
82	An update to: Pharmacological treatment for type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK . Diabet Med 2019; 36: 1063â€“1071. Diabetic Medicine, 2020, 37, 1405-1407.	1.2	0
83	Challenging 2019 ESC guidelines for the management of type 2 diabetes. Diabetes and Metabolism, 2020, 46, 181-185.	1.4	16

#	Article	IF	Citations
84	Cardiovascular risk and the implications for clinical practice of cardiovascular outcome trials in type 2 diabetes. Primary Care Diabetes, 2020, 14, 193-212.	0.9	7
85	Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11). Diabetes Therapy, 2020, 11, 53-70.	1.2	18
86	Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER). Diabetes, Obesity and Metabolism, 2020, 22, 355-364.	2.2	31
87	Efficacy and safety of onceâ€weekly exenatide after switching from twiceâ€daily exenatide in patients with typeÂ2 diabetes. Journal of Diabetes Investigation, 2020, 11, 382-388.	1.1	5
88	Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer antiâ€hyperglycaemic drug matters?. Diabetes, Obesity and Metabolism, 2020, 22, 149-157.	2.2	21
89	Glucagonâ€like peptideâ€1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated metaâ€analysis and subgroup analysis of randomized controlled trials. Diabetes, Obesity and Metabolism, 2020, 22, 203-211.	2.2	34
90	Oral semaglutide for type 2 diabetes: A systematic review and metaâ€analysis. Diabetes, Obesity and Metabolism, 2020, 22, 335-345.	2.2	54
91	The New Biology of Diabetic Kidney Diseaseâ€"Mechanisms and Therapeutic Implications. Endocrine Reviews, 2020, 41, 202-231.	8.9	77
92	Weight loss more than glycemic control may improve testosterone in obese type 2 diabetes mellitus men with hypogonadism. Andrology, 2020, 8, 654-662.	1.9	24
93	Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective. Diabetes Research and Clinical Practice, 2020, 160, 108008.	1.1	18
94	Advances in type 2 diabetes therapy: a focus on cardiovascular and renal outcomes. Medical Journal of Australia, 2020, 212, 133-139.	0.8	14
95	Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials. Diabetes Therapy, 2020, 11, 369-386.	1.2	48
96	2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2020, 63, 221-228.	2.9	368
97	Design and optimization strategies for the development of new drugs that treat chronic kidney disease. Expert Opinion on Drug Discovery, 2020, 15, 101-115.	2.5	13
98	The year in cardiology: cardiovascular prevention. European Heart Journal, 2020, 41, 1157-1163.	1.0	13
100	The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. Lancet Diabetes and Endocrinology,the, 2020, 8, 106-114.	5.5	77
101	REWIND to fast forward: time to revisit stroke prevention in type 2 diabetes?. Lancet Diabetes and Endocrinology,the, 2020, 8, 90-92.	5.5	5
102	Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. Diabetes, Obesity and Metabolism, 2020, 22, 442-451.	2.2	102

#	Article	IF	Citations
103	2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2020, 43, 487-493.	4.3	846
104	Preventing CKD in Developed Countries. Kidney International Reports, 2020, 5, 263-277.	0.4	72
105	Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. Cardiovascular Research, 2020, 116, 916-930.	1.8	51
106	Admission glucagon-like peptide-1 levels in acute myocardial infarction: is this a new biomarker of cardiovascular risk?. European Heart Journal, 2020, 41, 890-891.	1.0	1
107	For debate; pharmacological priorities in advanced type 2 diabetes. Journal of Diabetes and Its Complications, 2020, 34, 107510.	1.2	2
108	Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure. Metabolism: Clinical and Experimental, 2020, 104, 154045.	1.5	23
109	Renoprotection in diabetic kidney disease. Current Opinion in Nephrology and Hypertension, 2020, 29, 103-111.	1.0	0
110	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucoseâ€lowering drugs in patients with heart failure. European Journal of Heart Failure, 2020, 22, 196-213.	2.9	131
111	Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis. Stroke, 2020, 51, 666-669.	1.0	42
112	The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefit-risk relationship. Metabolism: Clinical and Experimental, 2020, 103, 154031.	1.5	12
113	Incretin therapy for diabetes mellitus type 2. Current Opinion in Endocrinology, Diabetes and Obesity, 2020, 27, 2-10.	1.2	21
115	Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?. Trends in Endocrinology and Metabolism, 2020, 31, 150-164.	3.1	21
116	Incretinâ€based glucoseâ€lowering medications and the risk of acute pancreatitis and malignancies: a metaâ€analysis based on cardiovascular outcomes trials. Diabetes, Obesity and Metabolism, 2020, 22, 699-704.	2.2	75
117	The right place for metformin today. Diabetes Research and Clinical Practice, 2020, 159, 107946.	1.1	29
118	Important Considerations for the Treatment of Patients with Diabetes Mellitus and Heart Failure from a Diabetologistâ€™s Perspective: Lessons Learned from Cardiovascular Outcome Trials. International Journal of Environmental Research and Public Health, 2020, 17, 155.	1.2	4
119	Long-acting GLP-1 receptor agonists. JAAPA: Official Journal of the American Academy of Physician Assistants, 2020, 33, 19-30.	0.1	6
120	An overview of the onceâ€weekly GLPâ€1 receptor agonists from the pharmacistâ€™s perspective. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 3-6.	0.7	1
121	Managing the multifaceted nature of type 2 diabetes using onceâ€weekly injectable GLPâ€1 receptor agonist therapy. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 7-16.	0.7	6

#	Article	IF	Citations
122	A review of GLPâ€1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of onceâ€weekly agents. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 17-27.	0.7	52
123	Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Cardiovascular Diabetology, 2020, 19, 156.	2.7	25
124	Secondary prevention after CABG: do new agents change the paradigm?. Current Opinion in Cardiology, 2020, 35, 664-672.	0.8	5
125	Glycaemic and nonâ€glycaemic efficacy of onceâ€weekly GLPâ€1 receptor agonists in people with type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 28-42.	0.7	8
126	Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. Circulation, 2020, 142, e265-e286.	1.6	107
127	The Effect of Dipeptidyl Peptidase-4 Inhibitors on Macrovascular and Microvascular Complications of Diabetes Mellitus: A Systematic Review. Current Therapeutic Research, 2020, 93, 100596.	0.5	19
128	KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International, 2020, 98, S1-S115.	2.6	692
129	Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis. Cardiovascular Diabetology, 2020, 19, 154.	2.7	21
130	A Review of the Current Evidence: Impact of Metabolic Surgery on Diabetes Outcomes and Obesity-Associated Macrovascular Complications. Current Diabetes Reports, 2020, 20, 57.	1.7	3
131	The dual glucoseâ€dependent insulinotropic peptide and glucagonâ€like peptideâ€1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 2451-2459.	2.2	83
132	Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance. Clinical Diabetes, 2020, 38, 390-402.	1.2	31
133	Chronic kidney disease as a cardiovascular risk factor. Journal of Hypertension, 2020, 38, 2110-2121.	0.3	21
134	Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis. Cardiovascular Diabetology, 2020, 19, 172.	2.7	9
135	Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. Metabolism: Clinical and Experimental, 2020, 111, 154343.	1.5	36
137	Efficacy and safety of saxagliptin for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2020, 21, 2101-2114.	0.9	3
138	GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms. Frontiers in Pharmacology, 2020, 11, 967.	1.6	52
139	Predicting and Preventing Myocardial Infarction in the Young. Diabetes Care, 2020, 43, 1679-1680.	4.3	0
140	Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. American Heart Journal, 2020, 229, 61-69.	1.2	137

#	Article	IF	Citations
141	Renal outcomes with the newer antidiabetes drugs: the era before and after CREDENCE. Diabetic Medicine, 2020, 37, 593-601.	1.2	3
144	Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin. European Heart Journal, 2021, 42, 2565-2573.	1.0	17
145	Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses. BMJ Open, 2020, 10, e037883.	0.8	6
146	Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 4221-4234.	1.1	13
147	Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk. Cardiovascular Diabetology, 2020, 19, 196.	2.7	52
148	Metformin: still the sweet spot for CV protection in diabetes?. Current Opinion in Pharmacology, 2020, 54, 202-208.	1.7	11
149	Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis. Cardiovascular Diabetology, 2020, 19, 199.	2.7	14
150	Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes. Annals of Internal Medicine, 2020, 172, 541.	2.0	53
151	The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism. Frontiers in Endocrinology, 2020, 11, 599355.	1.5	12
152	Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodiumâ€“glucose coâ€transporter 2 inhibitor therapy in <scp>DECLAREâ€TIMI</scp> 58. European Journal of Heart Failure, 2021, 23, 1026-1036.	2.9	35
153	How Do the Recent Major Randomized Controlled Trials Inform Best Use of the Novel Glucose-Lowering Agents?. Kidney and Blood Pressure Research, 2020, 45, 823-836.	0.9	1
154	Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black Patients. American Journal of Cardiology, 2020, 137, 133-135.	0.7	2
155	Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes. Annals of Internal Medicine, 2020, 173, 278-286.	2.0	182
156	Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline. Annals of Internal Medicine, 2020, 173, 813-821.	2.0	60
158	2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes. Journal of the American College of Cardiology, 2020, 76, 1117-1145.	1.2	276
159	Japanese Clinical Practice Guideline for Diabetes 2019. Journal of Diabetes Investigation, 2020, 11, 1020-1076.	1.1	159
160	Structural insights into probe-dependent positive allosterism of the GLP-1 receptor. Nature Chemical Biology, 2020, 16, 1105-1110.	3.9	58
161	The Impact of Diabetes Mellitus on Cardiovascular Risk Onset in Children and Adolescents. International Journal of Molecular Sciences, 2020, 21, 4928.	1.8	25

#	Article	IF	Citations
162	Japanese Clinical Practice Guideline for Diabetes 2019. Diabetology International, 2020, 11, 165-223.	0.7	266
163	Cardiovascular outcomes trials with glucagonâ€like peptideâ€1 receptor agonists: A comparison of study designs, populations and results. Diabetes, Obesity and Metabolism, 2020, 22, 2209-2226.	2.2	11
164	Subpopulation Differences in the Cardiovascular Efficacy of Long-Acting Glucagon-Like PeptideÂ1 Receptor Agonists in TypeÂ2 Diabetes Mellitus: A Systematic Review and Meta-analysis. Diabetes Therapy, 2020, 11, 2121-2143.	1.2	4
165	Effects of glucagonâ€like peptideâ€1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: Results of the <scp>LEADER</scp> and <scp>SUSTAIN</scp> 6 trials. Diabetes, Obesity and Metabolism, 2020, 22, 2487-2492.	2.2	31
167	Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists: a Review for the General Cardiologist. Current Cardiology Reports, 2020, 22, 105.	1.3	3
168	Targeting multiple domains of residual cardiovascular disease risk in patients with diabetes. Current Opinion in Cardiology, 2020, 35, 517-523.	0.8	2
169	Sodiumâ€“glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care. Current Opinion in Cardiology, 2020, 35, 589-601.	0.8	3
170	Patient-centered Management of Type 2 Diabetes Mellitus Based on Specific Clinical Scenarios: Systematic Review, Meta-analysis and Trial Sequential Analysis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, .	1.8	6
171	Importance de lâ€™Ã©valuation du risque cardiovasculaire pour une prÃ©conisation personnalisÃ©e des nouveaux traitements anti-hyperglycÃ©miants en prÃ©vention cardiovasculaire. Medecine Des Maladies Metaboliques, 2020, 14, 461-471.	0.1	0
172	Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovascular Diabetology, 2020, 19, 185.	2.7	83
173	Challenges and Strategies for Managing Diabetes in the Elderly in Long-Term Care Settings. Diabetes Spectrum, 2020, 33, 236-245.	0.4	14
174	Renal protection with glucagon-like peptide-1 receptor agonists. Current Opinion in Pharmacology, 2020, 54, 91-101.	1.7	22
175	Diabetic Kidney Disease. Primary Care - Clinics in Office Practice, 2020, 47, 645-659.	0.7	74
176	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetesâ€”2020. Diabetes Care, 2020, 43, S111-S134.	4.3	421
177	Use of Premixed Insulin, Metformin, and a Glucagon-Like Peptide 1 Receptor Agonist as a Therapeutic Approach for Uncontrolled Type 2 Diabetes. Diabetes Spectrum, 2020, 33, 182-189.	0.4	0
178	Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus. American Heart Journal, 2020, 229, 40-51.	1.2	4
179	New hypoglycaemic therapy in frail older people with diabetes mellitus-phenotypic status likely to be more important than functional status. Diabetes Research and Clinical Practice, 2020, 169, 108438.	1.1	3
180	Association of Glycemic Indices (Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic Complications. Journal of Diabetes Research, 2020, 2020, 1-17.	1.0	172

#	Article	IF	Citations
181	ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE. Nephrology, 2020, 25, 12-45.	0.7	17
182	A practical approach to the clinical challenges in initiation of basal insulin therapy in people with type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2021, 37, e3418.	1.7	14
184	Safety and tolerability of onceâ€weekly GLPâ€1 receptor agonists in type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 43-60.	0.7	47
185	Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012â€“2018. BMJ Open Diabetes Research and Care, 2020, 8, e001279.	1.2	41
186	Oral Semaglutide, A New Option in the Management of Type 2 Diabetes Mellitus: A Narrative Review. Advances in Therapy, 2020, 37, 4165-4174.	1.3	4
187	Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies. Diabetes Therapy, 2020, 11, 2221-2235.	1.2	14
188	Incidence of Hospitalization for Heart Failure Relative to Major Atherosclerotic Events in Type 2 Diabetes: A Meta-analysis of Cardiovascular Outcomes Trials. Diabetes Care, 2020, 43, 2614-2623.	4.3	9
189	Cardiovascular safety outcomes of onceâ€weekly GLPâ€1 receptor agonists in people with type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics, 2020, 45, 61-72.	0.7	9
190	Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease. American Journal of Nephrology, 2020, 51, 806-814.	1.4	16
191	ANDREW: A Multicenter, Prospective, Observational Study in Patients with Type 2 Diabetes on Persistent Treatment with Dulaglutide. Diabetes Therapy, 2020, 11, 2677-2690.	1.2	2
192	Diabetes, pre-diabetes and cardiovascular diseases in light of the 2019 ESC Guidelines. Studia Medyczne, 2020, 36, 148-155.	0.0	0
193	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure. Circulation, 2020, 142, 1205-1218.	1.6	63
194	Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3613-3682.	1.8	63
195	Metabolic effects of antihyperglycemic agents and mortality: meta-analysis of randomized controlled trials. Scientific Reports, 2020, 10, 12837.	1.6	4
197	Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy. Postgraduate Medicine, 2020, 132, 26-36.	0.9	12
198	Cardiometabolic medicine â€“ the US perspective on a new subspecialty. Cardiovascular Endocrinology and Metabolism, 2020, 9, 70-80.	0.5	12
199	Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with TypeÂ2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies. Diabetes Therapy, 2020, 11, 2329-2339.	1.2	2
200	GLP-1RAs and SGLT2is Reduce Cardiovascular Events Independent of Reductions of Systolic Blood Pressure and Body Weight: A Meta-Analysis with Meta-Regression. Diabetes Therapy, 2020, 11, 2429-2440.	1.2	13

#	Article	IF	Citations
201	Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia, 2020, 63, 2434-2445.	2.9	115
202	Diabetes in ageing: pathways for developing the evidence base for clinical guidance. Lancet Diabetes and Endocrinology,the, 2020, 8, 855-867.	5.5	47
203	Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. The Cochrane Library, 2020, 2020, CD009966.	1.5	9
204	Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update. Canadian Journal of Diabetes, 2020, 44, 575-591.	0.4	98
205	Pharmacologic Glycemic Management of Type 2 Diabetes in Adults: 2020 Update â€“ The Userâ€™s Guide. Canadian Journal of Diabetes, 2020, 44, 592-596.	0.4	12
206	Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients. Postgraduate Medicine, 2020, 132, 37-47.	0.9	10
207	Diabetes and CVD Risk: Special Considerations in African Americans Related to Care. Current Cardiovascular Risk Reports, 2020, 14, 1.	0.8	8
208	Diabetes medication regimens and patient clinical characteristics in the national patientâ€centered clinical research network, PCORnet. Pharmacology Research and Perspectives, 2020, 8, e00637.	1.1	8
209	Long-acting GLP-1RAs. JAAPA: Official Journal of the American Academy of Physician Assistants, 2020, 33, 3-18.	0.1	16
210	Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting. Advances in Therapy, 2020, 37, 4427-4445.	1.3	10
211	Repurposing Antidiabetic Drugs for Cardiovascular Disease. Frontiers in Physiology, 2020, 11, 568632.	1.3	25
212	Cardiac Computed Tomography for Personalized Management of Patients With Type 2 Diabetes Mellitus. Circulation: Cardiovascular Imaging, 2020, 13, e011365.	1.3	16
213	Novel therapeutic agents for the treatment of diabetic kidney disease. Expert Opinion on Investigational Drugs, 2020, 29, 1277-1293.	1.9	11
214	Prescribing Paradigm Shift? Damned If You Do, Damned If You Donâ€™t. Diabetes Care, 2020, 43, 1991-1993.	4.3	0
215	GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date. Postgraduate Medicine, 2020, 132, 3-14.	0.9	36
216	Integrating oral semaglutide into clinical practice in primary care: for whom, when, and how?. Postgraduate Medicine, 2020, 132, 48-60.	0.9	15
217	Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes compared with other oral antihyperglycemic agents and placebo. Postgraduate Medicine, 2020, 132, 15-25.	0.9	8
218	Prescription trends and costs of diabetes medications in Australia between 2003 and 2019: an analysis and review of the literature. Internal Medicine Journal, 2022, 52, 841-847.	0.5	5

#	Article	IF	Citations
219	Diabetes, metformin and glucose lowering therapies after myocardial infarction: Insights from the SWEDEHEART registry. Diabetes and Vascular Disease Research, 2020, 17, 147916412097367.	0.9	9
220	The role of intracoronary imaging in translational research. Cardiovascular Diagnosis and Therapy, 2020, 10, 1480-1507.	0.7	3
221	Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS. International Journal of Molecular Sciences, 2020, 21, 9554.	1.8	15
222	The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy. Frontiers in Physiology, 2020, 11, 603247.	1.3	11
223	Notable Underlying Mechanism for Pancreatic Î²-Cell Dysfunction and Atherosclerosis: Pleiotropic Roles of Incretin and Insulin Signaling. International Journal of Molecular Sciences, 2020, 21, 9444.	1.8	3
225	Effects of glucagon-like peptide 1 receptor agonists and sodium glucose cotransporter 2 inhibitors on major adverse cardiovascular events in type 2 diabetes by race, ethnicity, and region. Medicine (United States), 2020, 99, e23489.	0.4	7
226	Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy. Circulation, 2021, 143, 770-779.	1.6	47
227	Peptide YY (PYY) Is Associated with Cardiovascular Risk in Patients with Acute Myocardial Infarction. Journal of Clinical Medicine, 2020, 9, 3952.	1.0	5
228	Nurse Practitionerâ€“Directed Cardio-Diabetes Pilot Program. Journal for Nurse Practitioners, 2020, 16, e123-e128.	0.4	1
230	Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial. Diabetes Care, 2020, 43, 1546-1552.	4.3	92
231	Weight-centric pharmacological management of type 2 diabetes mellitus â€“ An essential component of cardiovascular disease prevention. Journal of Diabetes and Its Complications, 2020, 34, 107619.	1.2	11
232	The Emerging Role of Gut Dysbiosis in Cardio-metabolic Risk Factors for Heart Failure. Current Hypertension Reports, 2020, 22, 38.	1.5	19
233	Recommendations for management of diabetes during Ramadan: update 2020, applying the principles of the ADA/EASD consensus. BMJ Open Diabetes Research and Care, 2020, 8, e001248.	1.2	65
234	Insights into incretin-based therapies for treatment of diabetic dyslipidemia. Advanced Drug Delivery Reviews, 2020, 159, 34-53.	6.6	21
235	Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel. Diabetes, Obesity and Metabolism, 2020, 22, 1705-1713.	2.2	17
236	Combining Glucagon-Like Peptide 1 Receptor Agonists and Sodiumâ€“Glucose Cotransporter 2 Inhibitors to Target Multiple Organ Defects in Type 2 Diabetes. Diabetes Spectrum, 2020, 33, 165-174.	0.4	12
237	The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 394-404.	1.4	16
238	Computing and interpreting the Number Needed to Treat for Cardiovascular Outcomes Trials. Cardiovascular Diabetology, 2020, 19, 65.	2.7	15

#	Article	IF	Citations
239	Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes. Postgraduate Medicine, 2020, 132, 337-345.	0.9	13
240	Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials. Lancet Diabetes and Endocrinology,the, 2020, 8, 418-435.	5.5	105
241	Cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in Asians with type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 715-722.	1.8	16
242	Commentary: Glucose control: Not just a bystander in GLP-1RA-mediated cardiovascular protection. Metabolism: Clinical and Experimental, 2020, 109, 154272.	1.5	8
243	Advances in the management of diabetes: therapies for type 2 diabetes. Postgraduate Medical Journal, 2020, 96, 610-618.	0.9	11
244	Cardioprotective effects of GLPâ€1(28â€36a): A degraded metabolite or GLPâ€1â€™s better half?. Journal of Diabetes Investigation, 2020, 11, 1422-1425.	1.1	2
245	Metabolomics and Proteomics in Type 2 Diabetes. Circulation Research, 2020, 126, 1613-1627.	2.0	81
246	Basic Mechanisms of Diabetic Heart Disease. Circulation Research, 2020, 126, 1501-1525.	2.0	279
247	Review of the veteran affairs diabetes trial: Lessons learned. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 537-546.	2.6	0
248	Early biomarkers of diabetic kidney disease. A focus on albuminuria and a new combination of antidiabetic agents. International Journal of Clinical Practice, 2020, 74, e13586.	0.8	3
249	Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice. Cardiovascular Diabetology, 2020, 19, 74.	2.7	26
250	Comparative cardiovascular safety of GLP-1 receptor agonists versus other glucose-lowering agents in real-world patients with type 2 diabetes: a nationwide population-based cohort study. Cardiovascular Diabetology, 2020, 19, 83.	2.7	25
251	Pleiotropic effects of antidiabetic agents on renal and cardiovascular outcomes: a meta-analysis of randomized controlled trials. International Urology and Nephrology, 2020, 52, 1733-1745.	0.6	3
252	Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Lancet Neurology, The, 2020, 19, 582-590.	4.9	123
253	Adjunct therapies in treatment of type 1 diabetes. Journal of Diabetes, 2020, 12, 742-753.	0.8	17
254	Clinical efficacy and predictors of response to dulaglutide in type-2 diabetes. Pharmacological Research, 2020, 159, 104996.	3.1	15
255	Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis. Cardiovascular Diabetology, 2020, 19, 96.	2.7	15
256	The treament of hyperglycemia in acute ischemic stroke with incretin-based drugs. Pharmacological Research, 2020, 160, 105018.	3.1	5

#	Article	IF	Citations
257	Portuguese-Brazilian evidence-based guideline on the management of hyperglycemia in type 2 diabetes mellitus. Diabetology and Metabolic Syndrome, 2020, 12, 45.	1.2	10
258	Cardio-renal protection in older people with diabetes with frailty and medical comorbidities - A focus on the new hypoglycaemic therapy. Journal of Diabetes and Its Complications, 2020, 34, 107639.	1.2	17
259	No effects of a 6â€week intervention with a glucagonâ€like peptideâ€1 receptor agonist on pancreatic volume and oedema in obese men without diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1837-1846.	2.2	4
260	Diabetes and coronary artery disease: not just a risk factor. Heart, 2020, 106, 1357-1364.	1.2	13
262	Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering medications. Cardiovascular Endocrinology and Metabolism, 2020, 9, 56-59.	0.5	20
263	Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease. JAMA Cardiology, 2020, 5, 1182.	3.0	59
264	Effect of shortâ€acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized doubleâ€blind placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 1639-1647.	2.2	3
265	Using adult stem cells to monitor endothelial dysfunction in diabetes mellitus. Journal of Diabetes and Its Complications, 2020, 34, 107588.	1.2	9
266	Semaglutide injection for the treatment of adults with type 2 diabetes. Expert Review of Clinical Pharmacology, 2020, 13, 675-684.	1.3	8
267	Rationale for Timely Insulin Therapy in TypeÂ2 Diabetes Within the Framework of Individualised Treatment: 2020 Update. Diabetes Therapy, 2020, 11, 1645-1666.	1.2	27
268	Significance of SGLT2 inhibitors: lessons from renal clinical outcomes in patients with type 2 diabetes and basic researches. Diabetology International, 2020, 11, 245-251.	0.7	13
269	Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1678-1688.	2.2	34
270	Summarizing 2019 in Cardiovascular Prevention using the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Diseaseâ€™s â€˜ABCâ€™s Approach. American Journal of Preventive Cardiology, 2020, 2, 100027.	1.3	6
271	An emerging new concept for the management of type 2 diabetes with a paradigm shift from the glucose-centric to beta cell-centric concept of diabetes - an Asian perspective. Expert Opinion on Pharmacotherapy, 2020, 21, 1565-1577.	0.9	13
272	Effect of liraglutide on lipids in patients with type 2 diabetes: a pilot study. Endocrine Journal, 2020, 67, 957-962.	0.7	7
273	Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis. International Journal of Molecular Sciences, 2020, 21, 1907.	1.8	42
274	The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes. Diabetes Therapy, 2020, 11, 835-844.	1.2	27
275	Invited review. Series: Implications of the recent CVOTs in type 2 diabetes. Diabetes Research and Clinical Practice, 2020, 162, 108112.	1.1	21

#	Article	IF	Citations
276	Toxicity of Metformin and Hypoglycemic Therapies. Advances in Chronic Kidney Disease, 2020, 27, 18-30.	0.6	16
277	A randomized, openâ€label, active comparator trial assessing the effects of 26â€‰weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes. Diabetes, Obesity and Metabolism, 2020, 22, 1187-1196.	2.2	13
278	Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials. Expert Review of Clinical Pharmacology, 2020, 13, 461-468.	1.3	12
279	Noninsulin Therapy for Diabetes. Physician Assistant Clinics, 2020, 5, 153-165.	0.1	0
280	Effects of Liraglutide on CardiovascularÂOutcomes in Patients With Diabetes With or Without HeartÂFailure. Journal of the American College of Cardiology, 2020, 75, 1128-1141.	1.2	53
281	Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity. Journal of the Endocrine Society, 2020, 4, bvz042.	0.1	61
282	Leveraging the Gut to Treat Metabolic Disease. Cell Metabolism, 2020, 31, 679-698.	7.2	53
283	Incretin combination therapy for the treatment of nonâ€alcoholic steatohepatitis. Diabetes, Obesity and Metabolism, 2020, 22, 1328-1338.	2.2	26
284	Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. Circulation, 2020, 141, 1360-1370.	1.6	9
285	New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective. Metabolism: Clinical and Experimental, 2020, 107, 154218.	1.5	10
287	Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy. Diabetes, Obesity and Metabolism, 2020, 22, 1243-1262.	2.2	13
288	GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis. Journal of Neurology, 2020, 267, 2117-2122.	1.8	27
289	Sodiumâ€“glucose coâ€transporterâ€2 inhibitor cardiovascular outcome trials and generalizability to English primary care. Diabetic Medicine, 2020, 37, 1499-1508.	1.2	5
290	Effects of Liraglutide on Myocardial Function After Cardiac Surgery: A Secondary Analysis of the Randomised Controlled GLOBE Trial. Journal of Clinical Medicine, 2020, 9, 673.	1.0	4
292	Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management. Current Hepatology Reports, 2020, 19, 315-326.	0.4	11
293	Pharmacological therapies to address obesity in type 1 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2020, 27, 194-206.	1.2	7
294	Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study. Cardiovascular Diabetology, 2020, 19, 107.	2.7	18
295	Practical guidance for use of oral semaglutide in primary care: a narrative review. Postgraduate Medicine, 2020, 132, 687-696.	0.9	4

#	Article	IF	Citations
296	2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. Journal of the Chinese Medical Association, 2020, 83, 587-621.	0.6	7
297	Review article: the impact of liverâ€directed therapies on the atherogenic risk profile in nonâ€alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2020, 52, 619-636.	1.9	6
298	Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiologyâ€“Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodiumâ€“Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or) Tj ETQq0 0 0 rgBT /Overlock 10	4.3	13
299	Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life. BMJ Open Diabetes Research and Care, 2020, 8, e001451.	1.2	48
303	Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?. Diabetes Therapy, 2020, 11, 1627-1638.	1.2	8
304	LEADER Trial Eligibility and Preventable Cardiovascular Events in US Adults with Diabetes: the National Health and Nutrition Examination Surveys 2007â€“2016. Cardiovascular Drugs and Therapy, 2020, 34, 737-743.	1.3	2
305	Magnetically-driven implantable pump for on-demand bolus infusion of short-acting glucagon-like peptide-1 receptor agonist. Journal of Controlled Release, 2020, 325, 111-120.	4.8	8
306	Primary Care Physiciansâ€™ Knowledge of the Cardiovascular Effects of Diabetes Medications: Findings from an Online Survey. Advances in Therapy, 2020, 37, 3630-3639.	1.3	5
307	Discovery and pharmacology of the covalent GLP-1 receptor (GLP-1R) allosteric modulator BETP: A novel tool to probe GLP-1R pharmacology. Advances in Pharmacology, 2020, 88, 173-191.	1.2	10
308	GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection. Advances in Experimental Medicine and Biology, 2020, 1307, 193-212.	0.8	24
309	Treatment paradigm shifting implications of recent cardiovascular outcome trials: Core insights on the brink of the 2020ies. Diabetes Research and Clinical Practice, 2020, 161, 108054.	1.1	10
310	Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. European Journal of Preventive Cardiology, 2020, 27, 1922-1930.	0.8	15
311	Impact on guidelines: The general practitioner point of view. Diabetes Research and Clinical Practice, 2020, 166, 108091.	1.1	4
313	Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 181-187.	1.8	63
314	Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 433-438.	1.1	13
315	Effectiveness of dulaglutide vs liraglutide and exenatide once-weekly. A real-world study and meta-analysis of observational studies. Metabolism: Clinical and Experimental, 2020, 106, 154190.	1.5	20
316	GIP as a Potential Therapeutic Target for Atherosclerotic Cardiovascular Diseaseâ€“A Systematic Review. International Journal of Molecular Sciences, 2020, 21, 1509.	1.8	29
317	GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials. Endocrine, 2020, 68, 518-525.	1.1	35

#	Article	IF	Citations
318	Evaluating glucoseâ€lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial. Diabetes, Obesity and Metabolism, 2020, 22, 1231-1242.	2.2	13
320	Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials. European Heart Journal, 2020, 41, 3346-3358.	1.0	90
321	MÃ©dicaments hypoglycÃ©miants dans le diabÃ¨te de typeÂ2 et nÃ©phroprotectionÂ: un nouvel axe thÃ©rapeutiqueÂ?. Medecine Des Maladies Metaboliques, 2020, 14, 77-84.	0.1	0
323	Number Needed-to-Treat (NNT): Is it a necessary marker of therapeutic efficiency?. Diabetes and Metabolism, 2020, 46, 261-264.	1.4	5
324	Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice: The case of glucagonâ€like peptideâ€1 receptor agonists. Diabetes, Obesity and Metabolism, 2020, 22, 817-827.	2.2	19
325	Cardiovascular Risks and Benefits of Medications Used for Weight Loss. Frontiers in Endocrinology, 2019, 10, 883.	1.5	12
326	Liraglutide as addâ€on to sodiumâ€glucose coâ€transporterâ€2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRAâ€ADD2SGLT2i, a 26â€week, randomized, doubleâ€blind, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2020, 22, 929-937.	2.2	29
327	Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus. Circulation, 2020, 141, 843-862.	1.6	62
328	Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study. Diabetologia, 2020, 63, 1043-1054.	2.9	18
329	Dulaglutide: A Review in Type 2 Diabetes. Drugs, 2020, 80, 197-208.	4.9	19
330	The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes. Diabetology International, 2020, 11, 76-86.	0.7	20
331	Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of 21 randomized controlled trials. Endocrine, 2020, 68, 508-517.	1.1	6
332	The Short-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Sitagliptin and Once-Weekly Dulaglutide for the Treatment of Patients with TypeÂ2 Diabetes: A Cost of Control Analysis in Spain. Diabetes Therapy, 2020, 11, 509-521.	1.2	8
333	GLP1 Receptor Agonist and SGLT2 Inhibitor Combination: An Effective Approach in Real-world Clinical Practice. Clinical Therapeutics, 2020, 42, e1-e12.	1.1	15
334	Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps. Journal of the American College of Cardiology, 2020, 75, 539-555.	1.2	58
335	Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM. Journal of the Endocrine Society, 2020, 4, bvaa037.	0.1	18
336	Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. CJC Open, 2020, 2, 402-415.	0.7	6
337	Diabetic Agents, From Metformin toÂSGLT2 Inhibitors and GLP1ÂReceptorÂAgonists. Journal of the American College of Cardiology, 2020, 75, 1956-1974.	1.2	48

#	Article	IF	Citations
338	Glycaemic Control and Vascular Complications in Diabetes Mellitus Type 2. Advances in Experimental Medicine and Biology, 2020, 1307, 129-152.	0.8	31
340	Acute Exenatide Therapy Attenuates Postprandial Vasodilation in Humans with Prediabetes: A Randomized Controlled Trial. Metabolic Syndrome and Related Disorders, 2020, 18, 225-233.	0.5	3
341	Reduction of cardiovascular risk in patients with T2DM by GLP-1 receptor agonists: a shift in paradigm driven by data from large cardiovascular outcome trials. European Heart Journal, 2020, 41, 3359-3362.	1.0	7
342	<scp>GLP</scp>â€1 and insulin regulation of skeletal and cardiac muscle microvascular perfusion in type 2 diabetes. Journal of Diabetes, 2020, 12, 488-498.	0.8	17
343	ADVANCE in context: The benefits, risks and feasibility of providing intensive glycaemic control based on gliclazide modified release. Diabetes, Obesity and Metabolism, 2020, 22, 5-11.	2.2	12
344	Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets. Diabetes, Obesity and Metabolism, 2020, 22, 16-31.	2.2	91
345	An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. Diabetes, Obesity and Metabolism, 2020, 22, 3-15.	2.2	278
346	Relationship between improvement of glycaemic control and reduction of major cardiovascular events in 15 cardiovascular outcome trials: A metaâ€analysis with metaâ€regression. Diabetes, Obesity and Metabolism, 2020, 22, 1397-1405.	2.2	27
347	Efficacy, safety and cardiovascular outcomes of onceâ€daily oral semaglutide in patients with type 2 diabetes: The <scp>PIONEER</scp> programme. Diabetes, Obesity and Metabolism, 2020, 22, 1263-1277.	2.2	68
348	An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgraduate Medical Journal, 2020, 96, 156-161.	0.9	113
349	GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Frontiers in Endocrinology, 2020, 11, 178.	1.5	137
350	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm â€“ 2020 Executive Summary. Endocrine Practice, 2020, 26, 107-139.	1.1	410
351	The Place of Sulfonylureas in Guidelines: Why Are There Differences?. Diabetes Therapy, 2020, 11, 5-14.	1.2	9
352	Cardiovascular protection with sodiumâ€glucose coâ€transporterâ€2 inhibitors in type 2 diabetes: Does it apply to all patients?. Diabetes, Obesity and Metabolism, 2020, 22, 1481-1495.	2.2	17
354	Coronavirus Infections and Type 2 Diabetesâ€”Shared Pathways with Therapeutic Implications. Endocrine Reviews, 2020, 41, .	8.9	314
356	Novel glucose lowering agents are associated with a lower risk of cardiovascular and adverse events in type 2 diabetes: A population based analysis. International Journal of Cardiology, 2020, 310, 147-154.	0.8	5
357	Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?. Metabolism: Clinical and Experimental, 2020, 107, 154242.	1.5	17
358	Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study . ClinicoEconomics and Outcomes Research, 2020, Volume 12, 177-189.	0.7	9

#	Article	IF	Citations
359	Type 2 diabetes mellitus and cardiovascular disease: focus on the effect of antihyperglycemic treatments on cardiovascular outcomes. Expert Review of Cardiovascular Therapy, 2020, 18, 187-199.	0.6	1
360	Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes. Expert Review of Endocrinology and Metabolism, 2020, 15, 147-157.	1.2	12
361	Second revolution in cardiovascular prevention. Journal of the Chinese Medical Association, 2020, 83, 327-336.	0.6	6
362	Effectiveness of Dulaglutide in the Real World and in Special Populations of Type 2 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2617-e2625.	1.8	17
363	Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagonâ€Like Peptideâ€1 Receptor Agonist and Sodiumâ€Glucose Cotransporterâ€2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Metaâ€Analysis. Journal of the American Heart Association, 2020, 9, e015323.	1.6	22
364	Effects of Basal Insulin on Lipid Profile Compared to Other Classes of Antihyperglycemic Agents in Type 2 Diabetic Patients. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2464-2474.	1.8	7
365	Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 465-473.	2.2	32
366	GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists. Journal of Clinical Medicine, 2020, 9, 947.	1.0	85
367	Time to Rethink Reducing Cardiovascular Risk: Are We Ready?. Canadian Journal of Diabetes, 2020, 44, 1-3.	0.4	2
368	A disease state approach to the pharmacological management of Type 2 diabetes in primary care: A position statement by Primary Care Diabetes Europe. Primary Care Diabetes, 2021, 15, 31-51.	0.9	27
369	Changing Fields-Diabetes Medications Invading the Cardiovascular Space. Current Problems in Cardiology, 2021, 46, 100736.	1.1	1
370	Realâ€world use of cardioprotective glucoseâ€lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019. Diabetes, Obesity and Metabolism, 2021, 23, 520-529.	2.2	19
371	Management of postâ€transplant diabetes: immunosuppression, early prevention, and novel antidiabetics. Transplant International, 2021, 34, 27-48.	0.8	57
372	Optimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach. Diabetes Spectrum, 2021, 34, 7-19.	0.4	5
373	Guideline recommendations and the positioning of newer drugs in type 2 diabetes care. Lancet Diabetes and Endocrinology,the, 2021, 9, 46-52.	5.5	103
374	Diabetes Mellitus and Noncardiac Atherosclerotic Vascular Diseaseâ€"Pathogenesis and Pharmacological Treatment Options. Journal of Cardiovascular Pharmacology and Therapeutics, 2021, 26, 25-39.	1.0	13
375	Design and baseline characteristics of the <scp>AMPLITUDEâ€O</scp> cardiovascular outcomes trial of efpeglenatide, a weekly glucagonâ€like peptideâ€1 receptor agonist. Diabetes, Obesity and Metabolism, 2021, 23, 318-323.	2.2	12
376	Switching between GLPâ€1 receptor agonists in clinical practice: Expert consensus and practical guidance. International Journal of Clinical Practice, 2021, 75, e13731.	0.8	22

#	Article	IF	Citations
377	PrevenciÃ³n de ictus en pacientes con diabetes mellitus tipo 2 o prediabetes. Recomendaciones del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad EspaÃ±ola de NeurologÃa. NeurologÃa, 2021, 36, 305-323.	0.3	5
378	GLP-1 receptor agonists in the treatment of type 2 diabetes â€“ state-of-the-art. Molecular Metabolism, 2021, 46, 101102.	3.0	518
379	Anticipatory guidance and systematic review of prescribing combination incretin therapy in the treatment of type 2 diabetes. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 28-34.	0.7	1
380	SGLT-2 inhibitors may be targeting higher risk patients with diabetes possibly justifying higher cost: Single center repeated cross-sectional analysis. Journal of Diabetes and Its Complications, 2021, 35, 107761.	1.2	3
381	Comparison of the effects of 10 GLP-1 RA and SGLT2 inhibitor interventions on cardiovascular, mortality, and kidney outcomes in type 2 diabetes: A network meta-analysis of large randomized trials. Primary Care Diabetes, 2021, 15, 208-211.	0.9	29
382	Efficacy and safety of onceâ€weekly semaglutide versus onceâ€daily sitagliptin as addâ€on to metformin in patients with type 2 diabetes in <scp>SUSTAIN China</scp>: A 30â€week, doubleâ€blind, phase 3a, randomized trial. Diabetes, Obesity and Metabolism, 2021, 23, 404-414.	2.2	45
383	Association of Diabetes Mellitus and Cholangiocarcinoma: Update of Evidence and the Effects of Antidiabetic Medication. Canadian Journal of Diabetes, 2021, 45, 282-290.	0.4	8
384	Practical Considerations and Rationale for Glucagon-Like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes. Canadian Journal of Diabetes, 2021, 45, 291-302.	0.4	9
385	Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 912-921.	1.8	27
386	Adoption of the ADA/EASD guidelines in 10 Eastern and Southern European countries: Physician survey and good clinical practice recommendations from an international expert panel. Diabetes Research and Clinical Practice, 2021, 172, 108535.	1.1	14
387	Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nature Reviews Nephrology, 2021, 17, 227-244.	4.1	87
388	Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. Annals of Internal Medicine, 2021, 174, 385-394.	2.0	110
389	COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nature Reviews Endocrinology, 2021, 17, 11-30.	4.3	653
390	NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes and Metabolism, 2021, 47, 101215.	1.4	84
391	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetesâ€”2021. Diabetes Care, 2021, 44, S125-S150.	4.3	359
392	External validity of type 2 diabetes clinical trials on cardiovascular outcomes for a multimorbid population. Diabetes, Obesity and Metabolism, 2021, 23, 971-979.	2.2	2
393	Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis. Kidney360, 2021, 2, 254-262.	0.9	14
394	Diagnosis, prevention, and treatment of cardiovascular diseases in people with type 2 diabetes and prediabetes: a consensus statement jointly from the Japanese Circulation Society and the Japan Diabetes Society. Diabetology International, 2021, 12, 1-51.	0.7	6

#	Article	IF	Citations
395	Preoperative considerations of new long-acting glucagon-like peptide-1 receptor agonists in diabetes mellitus. British Journal of Anaesthesia, 2021, 126, 567-571.	1.5	21
396	Glucoseâ€lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology. Diabetes/Metabolism Research and Reviews, 2021, 37, e3416.	1.7	7
397	Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes Mellitus. Clinical Pharmacokinetics, 2021, 60, 153-163.	1.6	3
398	Coronary Artery Calcium for Personalized Risk Managementâ€"A Second Chance for Aspirin in Primary Prevention?. JAMA Cardiology, 2021, 6, 187.	3.0	4
399	Clinical Impact of Weight-Loss Pharmacotherapy in Patients with Atherosclerotic Cardiovascular Disease. American Journal of Cardiovascular Drugs, 2021, 21, 271-281.	1.0	4
400	Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?. Primary Care Diabetes, 2021, 15, 59-68.	0.9	9
401	Review of Newer Antidiabetic Agents for Diabetes Management in Kidney Transplant Recipients. Annals of Pharmacotherapy, 2021, 55, 496-508.	0.9	17
402	Optimizing Management of Type 2 Diabetes and Its Complications in Patients With Heart Failure. Clinical Diabetes, 2021, 39, 105-116.	1.2	0
403	Glucagonâ€like peptideâ€1 (GLPâ€1) receptor agonists in type 2 diabetes and longâ€term complications: FOCUS on retinopathy. Diabetic Medicine, 2021, 38, e14390.	1.2	6
404	Glucagon-like peptide-1 receptor agonists as neuroprotective agents for ischemic stroke: a systematic scoping review. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 14-30.	2.4	25
405	Potential unrealized mortality benefit of glucagonâ€like peptideâ€1 receptor agonists and sodiumâ€glucose coâ€transportâ€2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program. Diabetes, Obesity and Metabolism, 2021, 23, 97-105.	2.2	1
406	Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology. Trends in Cardiovascular Medicine, 2021, 31, 49-56.	2.3	12
407	Antihyperglycemic therapies and cardiovascular outcomes in patients with type 2 diabetes mellitus: State of the art and future directions. Trends in Cardiovascular Medicine, 2021, 31, 101-108.	2.3	5
408	Cardiovascular Disease Epidemiology and Risk Factors: General Concepts. Contemporary Cardiology, 2021, , 1-22.	0.0	0
409	Diabetic kidney disease: update on clinical management and non-glycaemic effects of newer medications for type 2 diabetes. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882110206.	1.4	8
410	Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. Metabolites, 2021, 11, 73.	1.3	145
411	GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential. International Journal of Biological Sciences, 2021, 17, 2050-2068.	2.6	75
412	Prevention of Cardiovascular Disease. , 2021, , 33-54.		0

#	Article	IF	Citations
413	Comparative Efficacy of Glucagon-like Peptide 1 Receptor Agonists and Sodium Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular Events in Type 2 Diabetes: A Network Meta-analysis. Journal of Cardiovascular Pharmacology, 2021, 77, 34-37.	0.8	11
414	Current Status and Potential Therapeutic Strategies for Using Non-coding RNA to Treat Diabetic Cardiomyopathy. Frontiers in Physiology, 2020, 11, 612722.	1.3	11
415	Practical guidance on the initiation, titration, and switching of basal insulins: a narrative review for primary care. Annals of Medicine, 2021, 53, 999-1010.	1.5	8
416	Diabetes, Lipids, and CV Risk. Current Atherosclerosis Reports, 2021, 23, 8.	2.0	6
417	Dulaglutide exerts beneficial anti atherosclerotic effects in ApoE knockout mice with diabetes: the earlier, the better. Scientific Reports, 2021, 11, 1425.	1.6	16
418	The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study. Diabetes Care, 2021, 44, 1385-1392.	4.3	16
419	Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia. International Journal of Molecular Sciences, 2021, 22, 660.	1.8	15
420	Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial. Cardiovascular Diabetology, 2021, 20, 1.	2.7	59
421	Repurposing GLP-1 Receptor Agonists for Parkinsonâ€™s Disease: Current Evidence and Future Opportunities. Pharmaceutical Medicine, 2021, 35, 11-19.	1.0	5
422	Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with TypeÂ2 Diabetes: The PIONEERÂ10 Randomized, Active-Controlled Trial. Diabetes Therapy, 2021, 12, 613-623.	1.2	7
423	Comparative Effectiveness and Safety of Sodiumâ€“Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults. Diabetes Care, 2021, 44, 826-835.	4.3	66
425	Heterogeneity in renal endÂpoints of cardiovascular outcomes trials in Type 2 diabetes. Journal of Comparative Effectiveness Research, 2021, 10, 169-173.	0.6	1
426	Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019. JAMA Network Open, 2021, 4, e2035792.	2.8	46
427	Medical treatment of type 2 diabetes mellitus: Recommendations of the Diabetes, Obesity and Nutrition Group of the Spanish Society of Internal Medicine. Revista Clínica Espanõla, 2021, 221, 101-108.	0.3	4
428	Changing the approach to type 2 diabetes treatment: A comparison of glucagonâ€like peptideâ€1 receptor agonists and sulphonylureas across the continuum of care. Diabetes/Metabolism Research and Reviews, 2021, 37, e3434.	1.7	5
430	Coronary Artery Calcium for the Allocation of GLP-1RA for Primary Prevention of Atherosclerotic Cardiovascular Disease. JACC: Cardiovascular Imaging, 2021, 14, 1470-1472.	2.3	18
431	Novel GLP-1 analog supaglutide improves glucose homeostasis in diabetic monkeys. Journal of Endocrinology, 2021, 248, 145-154.	1.2	2
432	Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the <scp>EXSCEL</scp> and <scp>SAVORâ€TIMI</scp> 53 cardiovascular outcomes trials. Diabetes, Obesity and Metabolism, 2021, 23, 1101-1110.	2.2	4

#	Article	IF	Citations
433	Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model. Endocrinology and Metabolism, 2021, 36, 157-170.	1.3	11
434	Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis. Diabetes and Metabolism, 2021, 47, 101160.	1.4	6
435	The Safety of Pharmacological and Surgical Treatment of Diabetes in Patients with Diabetic Retinopathyâ€"A Review. Journal of Clinical Medicine, 2021, 10, 705.	1.0	9
436	Association of Gastric Bypass Surgery With Risk of Developing Diabetic Retinopathy Among Patients With Obesity and Type 2 Diabetes in Sweden. JAMA Ophthalmology, 2021, 139, 200.	1.4	9
437	Comprehensive Care Models for Cardiometabolic Disease. Current Cardiology Reports, 2021, 23, 22.	1.3	21
438	Sodiumâ€"glucose cotransporterÂ2 inhibitors in typeÂ2 diabetes patients with renal function impairment slow the annual renal function decline, in a real clinical practice. Journal of Diabetes Investigation, 2021, 12, 1577-1585.	1.1	6
439	A Pharmacist-Led Collaborative Care Model for Cardiometabolic Risk Reduction: A Case Study. ADCES in Practice, 2021, 9, 16-23.	0.2	0
440	Cardiometabolism as an Interlocking Puzzle between the Healthy and Diseased Heart: New Frontiers in Therapeutic Applications. Journal of Clinical Medicine, 2021, 10, 721.	1.0	19
441	Trends in Total and Out-of-pocket Payments for Noninsulin Glucose-Lowering Drugs Among U.S. Adults With Large-Employer Private Health Insurance From 2005 to 2018. Diabetes Care, 2021, 44, 925-934.	4.3	7
442	Glucagon-Like PeptideÂ1 Receptor Agonist (GLP1RA) Exposure and Outcomes in TypeÂ2 Diabetes: A Systematic Review of Population-Based Observational Studies. Diabetes Therapy, 2021, 12, 969-989.	1.2	9
443	Metabolic surgery: A clinical update. Diabetes, Obesity and Metabolism, 2021, 23, 63-83.	2.2	19
444	Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2021, 172, 108656.	1.1	22
445	GLPâ€1 RA and atrial fibrillation in the cardiovascular outcome trials. Diabetes/Metabolism Research and Reviews, 2021, 37, e3436.	1.7	10
446	Double Diabetes: A Growing Problem Requiring Solutions. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, 268-274.	0.6	5
447	Tratamiento mÃ©dico de la diabetes mellitus tipo 2: recomendaciones del Grupo de Diabetes, Obesidad y NutriciÃ³n de la Sociedad EspaÃ±ola de Medicina Interna. Revista Clinica Espanola, 2021, 221, 101-108.	0.2	4
449	Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?. Diabetes Care, 2021, 44, 641-646.	4.3	10
450	Efficacy and Safety of Dulaglutide in Older Patients: A post hoc Analysis of the REWIND trial. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1345-1351.	1.8	14
451	Prescribing in Type 2 Diabetes Patients With and Without Cardiovascular Disease History: AÂDescriptive Analysis in the UK CPRD. Clinical Therapeutics, 2021, 43, 320-335.	1.1	26

#	Article	IF	Citations
452	Current and future therapies for type 1 diabetes. Diabetologia, 2021, 64, 1037-1048.	2.9	65
453	The â€œEarly Treatmentâ€•Approach Reducing Cardiovascular Risk in Patients with TypeÂ2 Diabetes: A Consensus From an Expert Panel Using the Delphi Technique. Diabetes Therapy, 2021, 12, 1445-1461.	1.2	5
454	Diabetes Management in Patients with Heart Failure. Diabetes and Metabolism Journal, 2021, 45, 158-172.	1.8	9
455	Management of Diabetes 100 Years After the Discovery of Insulin: Nuances for the Kidney. Kidney Medicine, 2021, 3, 159-161.	1.0	0
456	Multifaceted Mechanisms of Action of Metformin Which Have Been Unraveled One after Another in the Long History. International Journal of Molecular Sciences, 2021, 22, 2596.	1.8	36
457	Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. Cardiovascular Diabetology, 2021, 20, 75.	2.7	9
458	Cardiovascular Effects of Hypoglycemic Agents in Diabetes Mellitus. Current Drug Safety, 2021, 16, 32-51.	0.3	1
459	Mechanisms and Potential Roles of Glucose-Lowering Agents in COVID-19: A Review. Annals of Pharmacotherapy, 2021, 55, 1386-1396.	0.9	3
460	Diabetes and Stroke. Journal of Korean Diabetes, 2021, 22, 26-37.	0.1	1
461	Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes. Journal of Clinical Medicine, 2021, 10, 985.	1.0	22
462	The effects of Glucagon Like Peptide-1 (GLP-1) on cardiac remodelling: exploring the role of medication and physiological modulation after metabolic surgery: a narrative review. Minerva Endocrinology, 2021, , .	0.6	2
463	Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: a Mendelian randomisation study and meta-analysis. Diabetologia, 2021, 64, 1492-1503.	2.9	13
464	Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. Diabetes Care, 2021, 44, 1159-1167.	4.3	25
465	Glucose-Lowering Medications and Cardiovascular Outcomes. Current Cardiology Reports, 2021, 23, 24.	1.3	2
466	Abnormal Glucose Tolerance in Prediabetes Patients with Acute Myocardial Infarction: Implications for Therapy. Journal of Endocrinological Science, 2021, 3, 16-21.	0.1	1
467	Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes. Cardiac Failure Review, 2021, 7, e04.	1.2	7
468	Are Chinese Patients with Type 2 Diabetes and a Body Mass Index of 27.5â€“32.5Âkg/m2 Suitable for Metabolic Surgery? A One-Year Post-Surgery Study. Diabetes Therapy, 2021, 12, 1429-1444.	1.2	1
469	Treating Arterial Ageing in Patients with Diabetes: From Mechanisms to Effective Drugs. International Journal of Molecular Sciences, 2021, 22, 2796.	1.8	10

#	Article	IF	Citations
470	Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes. ACS Omega, 2021, 6, 8271-8278.	1.6	11
471	A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease. European Cardiology Review, 2021, 16, e11.	0.7	2
472	Applying <scp>REWIND</scp> cardiovascular disease criteria to <scp>SUSTAIN</scp> 6 and <scp>PIONEER</scp> 6: An exploratory analysis of cardiovascular outcomes with semaglutide. Diabetes, Obesity and Metabolism, 2021, 23, 1677-1680.	2.2	4
473	SGLT2 Inhibitors and Other Novel Therapeutics in the Management of Diabetic Kidney Disease. Seminars in Nephrology, 2021, 41, 85-95.	0.6	2
474	Sex- and Gender-Based Pharmacological Response to Drugs. Pharmacological Reviews, 2021, 73, 730-762.	7.1	80
475	A review of glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor cardiovascular trials. Journal of the American Association of Nurse Practitioners, 2021, Publish Ahead of Print, 1139-1147.	0.5	0
476	Diabetes mellitus in combination with COVID-19: modern views on therapy. Reproductive Endocrinology, 2021, , 8-20.	0.0	0
477	Expert Consensus on Telemedicine Management of Diabetes (2020 Edition). International Journal of Endocrinology, 2021, 2021, 1-12.	0.6	12
479	Evolution and Outcomes of Premature Coronary Artery Disease. Current Cardiology Reports, 2021, 23, 36.	1.3	8
480	Effect of GLP-1/GLP-1R on the Polarization of Macrophages in the Occurrence and Development of Atherosclerosis. Mediators of Inflammation, 2021, 2021, 1-10.	1.4	10
481	Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome. Current Atherosclerosis Reports, 2021, 23, 16.	2.0	6
482	Real-world utilization of pharmacotherapy with new evidence-based cardiovascular indications in an academic preventive cardiology practice. American Journal of Preventive Cardiology, 2021, 5, 100144.	1.3	7
483	Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes. Diabetes Care, 2021, 44, 1236-1241.	4.3	37
484	Oral Semaglutide Reduces HbA1c and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses. Diabetes Therapy, 2021, 12, 1099-1116.	1.2	8
486	Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24Âmonths follow-up study. Diabetes Research and Clinical Practice, 2021, 173, 108681.	1.1	8
487	Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy. Expert Opinion on Drug Safety, 2021, 20, 475-480.	1.0	6
488	Lower risk of death and cardiovascular events in patients with diabetes initiating glucagonâ€like peptideâ€1 receptor agonists or sodiumâ€glucose cotransporterâ€2 inhibitors: A realâ€world study in two Italian cohorts. Diabetes, Obesity and Metabolism, 2021, 23, 1484-1495.	2.2	20
489	The Relationship Between Type 2 Diabetes, NAFLD, and Cardiovascular Risk. Current Diabetes Reports, 2021, 21, 15.	1.7	78

#	Article	IF	Citations
490	Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6. Frontiers in Endocrinology, 2021, 12, 645566.	1.5	42
491	An observational study evaluating effectiveness and therapeutic adherence in patients with Type 2 Diabetes initiating dulaglutide vs. subcutaneous semaglutide in Spain. Endocrine and Metabolic Science, 2021, 2, 100082.	0.7	4
492	Approvals of type 2 diabetes drugs tested in cardiovascular outcome trials: A tripartite comparison. British Journal of Clinical Pharmacology, 2021, 87, 3938-3948.	1.1	0
493	Newer anti-diabetic therapies with low hypoglycemic risk-potential advantages for frail older people. Hospital Practice (1995), 2021, 49, 164-175.	0.5	2
494	GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis. Diabetes Research and Clinical Practice, 2021, 174, 108737.	1.1	61
495	Cardiovascular Risk Reduction Following Metabolic and Bariatric Surgery. Surgical Clinics of North America, 2021, 101, 269-294.	0.5	11
496	Therapeutic Manipulation of Myocardial Metabolism. Journal of the American College of Cardiology, 2021, 77, 2022-2039.	1.2	40
497	The gutâ€“brain axis: Identifying new therapeutic approaches for type 2 diabetes, obesity, and related disorders. Molecular Metabolism, 2021, 46, 101175.	3.0	29
498	Loss of CASK Accelerates Heart Failure Development. Circulation Research, 2021, 128, 1139-1155.	2.0	11
499	Use of GLP1RAs and occurrence of respiratory disorders: A metaâ€analysis of large randomized trials of GLP1RAs. Clinical Respiratory Journal, 2021, 15, 847-850.	0.6	5
501	A Review of the Dose Justification of Phase 3 Trials to Regulatory Authorities for Drugs Intended for the Treatment of Type 2 Diabetes in Europe. Frontiers in Pharmacology, 2021, 12, 626766.	1.6	0
502	The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodiumâ€“glucose cotransporter 2 inhibitor. Cardiovascular Diabetology, 2021, 20, 93.	2.7	8
503	The changing landscape of atherosclerosis. Nature, 2021, 592, 524-533.	13.7	921
504	A narrative review of new treatment options for chronic kidney disease in type 2 diabetes. Annals of Translational Medicine, 2021, 9, 716-716.	0.7	5
505	Use of Anti-Diabetic Agents in Non-Diabetic Kidney Disease: From Bench to Bedside. Life, 2021, 11, 389.	1.1	7
506	GLP-1 Receptor Agonists in Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1578-1580.	2.2	11
507	Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes. New England Journal of Medicine, 2021, 384, 1248-1260.	13.9	60
508	From glucose lowering agents to disease/diabetes modifying drugs: a â€œSIMPLEâ€•approach for the treatment of type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 92.	2.7	28

#	Article	IF	Citations
510	The brain as an insulin-sensitive metabolic organ. Molecular Metabolism, 2021, 52, 101234.	3.0	84
511	Short-Term Excess Healthcare Costs Associated with Cardiovascular Events Among Adults with Type 2 Diabetes in Israel: A Retrospective Cohort Study. PharmacoEconomics - Open, 2021, 5, 533-544.	0.9	1
512	Diabetic heart disease: A clinical update. World Journal of Diabetes, 2021, 12, 383-406.	1.3	28
513	Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?. Drugs, 2021, 81, 881-893.	4.9	9
514	Effects of anti-diabetes medications on cardiovascular and kidney outcomes in Asian patients with type 2 diabetes: a rapid evidence assessment and narrative synthesis. Expert Opinion on Drug Safety, 2021, 20, 1-14.	1.0	6
515	Consensus Recommendations by the Asian Pacific Society of Cardiology: Optimising Cardiovascular Outcomes in Patients with Type 2 Diabetes. European Cardiology Review, 2021, 16, e14.	0.7	4
516	Evaluation of GLP-1 Receptor Agonists in Combination With Multiple Daily Insulin Injections for Type 2 Diabetes. Journal of Pharmacy Practice, 2022, 35, 979-990.	0.5	5
517	Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes. Diabetes Therapy, 2021, 12, 1613-1630.	1.2	8
519	Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus. Cardiovascular Diabetology, 2021, 20, 89.	2.7	9
520	Stroke prevention in patients with type 2 diabetes mellitus or prediabetes: recommendations of the Spanish Society of Neurologyâ€™s Stroke Study Group. NeurologÃa (English Edition), 2021, 36, 305-323.	0.2	2
521	Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?. Journal of Clinical Medicine, 2021, 10, 2040.	1.0	6
522	Series: Cardiovascular outcome trials for diabetes drugs Semaglutide and SUSTAIN-6. British Journal of Diabetes, 2021, 21, 110-112.	0.1	0
523	Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like PeptideÂ1 Receptor Agonists in Chinese Patients with TypeÂ2 Diabetes Mellitus. Diabetes Therapy, 2021, 12, 1861-1870.	1.2	5
524	Chronic kidney disease in patients with diabetes mellitus. Endocrine Connections, 2021, 10, R151-R159.	0.8	12
525	Glucagon-like peptide-1 receptor agonists and the cardiorenal axis in Type 2 diabetes: a focus on dulaglutide. Future Cardiology, 2021, 17, 459-473.	0.5	4
526	Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes. Diabetes Care, 2021, 44, 1252-1253.	4.3	3
527	A real-world comparison of cardiovascular, medical and costs outcomes in new users of SGLT2 inhibitors versus GLP-1 agonists. Diabetes Research and Clinical Practice, 2021, 175, 108800.	1.1	15
528	Cardiovascular outcomeÂtrials in Type 2 diabetes: food for thought. Future Cardiology, 2021, 17, 407-410.	0.5	1

#	Article	IF	Citations
529	RÃ©sultats des Ã©tudes cliniques de sÃ©curitÃ© cardiovasculaire avec les inhibiteurs des SGLT-2Âet les agonistes des rÃ©cepteurs du GLP-1Â: quels enseignementsÂ?. Medecine Des Maladies Metaboliques, 2021, 15, 252-259.	0.1	0
530	InterpretaciÃ³n de los ensayos clÃnicos sobre efectos cardiovasculares de los fÃ¡rmacos hipoglucemiantes en personas con diabetes tipo 2. Endocrinologia, Diabetes Y NutriciÃ“n, 2021, 68, 741-750.	0.1	0
531	Old Paradoxes and New Opportunities for Appetite Control in Obesity. Trends in Endocrinology and Metabolism, 2021, 32, 264-294.	3.1	22
532	Dapagliflozin and measures of cardiovascular autonomic function in patients with type 2 diabetes (T2D). Journal of Diabetes and Its Complications, 2021, 35, 107949.	1.2	4
533	Evaluation of Consistency of Treatment Response Across Regionsâ€"the LEADER Trial in Relation to the ICH E17 Guideline. Frontiers in Medicine, 2021, 8, 662775.	1.2	4
534	Novel therapies with precision mechanisms for type 2 diabetes mellitus. Nature Reviews Endocrinology, 2021, 17, 364-377.	4.3	70
535	Recent advances in new-onset diabetes mellitus after kidney transplantation. World Journal of Diabetes, 2021, 12, 541-555.	1.3	4
536	SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ, The, 2021, 373, n1091.	3.0	59
537	Challenges in Implementing Evidence Based Cross-Disciplinary Therapies: Are Cardiovascular Specialists Ready to Claim SGLT-2 Inhibitors and GLP-1 Analogs?. Current Problems in Cardiology, 2022, 47, 100878.	1.1	0
538	The impact of diabetes on heart failure development: The cardio-renal-metabolic connection. Diabetes Research and Clinical Practice, 2021, 175, 108831.	1.1	5
540	Delivering joined-up care for people with type 2 diabetes: rationale, challenges and examples. British Journal of Diabetes, 2021, 21, 89-95.	0.1	4
542	Glucose variability and diabetes complications: Risk factor or biomarker? Can we disentangle the â€œGordian Knotâ€?. Diabetes and Metabolism, 2021, 47, 101225.	1.4	34
543	A systematic review and meta-analysis of the impact of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiovascular outcomes in biologically healthy older adults. British Journal of Diabetes, 2021, 21, 30-35.	0.1	7
544	Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients. Scientific Reports, 2021, 11, 10166.	1.6	14
545	Risk of stent failure in patients with diabetes treated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors: A nationwide observational study. International Journal of Cardiology, 2021, 330, 23-29.	0.8	6
546	Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug. Cardiovascular Diabetology, 2021, 20, 109.	2.7	54
547	Soluble Epoxide Hydrolase Blockade after Stroke Onset Protects Normal but Not Diabetic Mice. International Journal of Molecular Sciences, 2021, 22, 5419.	1.8	11
548	Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications. Mitochondrion, 2021, 58, 72-82.	1.6	13

#	Article	IF	Citations
549	<scp>Glucagonâ€like peptideâ€1 receptor agonists</scp> improve biomarkers of inflammation and oxidative stress: A systematic review and metaâ€analysis of randomised controlled trials. Diabetes, Obesity and Metabolism, 2021, 23, 1806-1822.	2.2	53
550	Ambulatory <scp>noninsulin</scp> treatment of type 2 diabetes mellitus in the United States, 2015 to 2019. Diabetes, Obesity and Metabolism, 2021, 23, 1843-1850.	2.2	9
551	Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population. Clinical Therapeutics, 2021, 43, 808-821.	1.1	11
552	Exacerbation of atrial fibrillation related to dulaglutide use. Clinical Case Reports (discontinued), 2021, 9, e04223.	0.2	3
553	A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes. Drugs, 2021, 81, 1003-1030.	4.9	27
554	Cardiovascular impact of new drugs (GLP-1 and gliflozins): the ABCD position statement. British Journal of Diabetes, 2021, 21, 132-148.	0.1	0
555	A year in diabetic nephropathy. British Journal of Diabetes, 2021, 21, 100-109.	0.1	0
556	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). Eurasian Heart Journal, 2021, , 6-61.	0.2	9
558	Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes. Cardiovascular Diabetology, 2021, 20, 103.	2.7	3
559	Glucagonâ€like peptideâ€1 (GLPâ€1) receptor agonists and their cardiovascular benefitsâ€”The role of the GLPâ€1 receptor. British Journal of Pharmacology, 2022, 179, 659-676.	2.7	28
560	Metformin in the era of new antidiabetics. Future Cardiology, 2021, 17, 475-485.	0.5	2
561	Role of coronary artery calcium score in the primary prevention of cardiovascular disease. BMJ, The, 2021, 373, n776.	3.0	60
562	Efficacy of dulaglutide: an evidence-based review of its potential indications. Meditsinskiy Sovet, 2021, , 18-30.	0.1	0
563	How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR. Journal of Clinical Medicine, 2021, 10, 2505.	1.0	17
564	Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. Pharmacological Reviews, 2021, 73, 924-967.	7.1	359
565	Recent Updates on Glucagon-Like Peptide 1 Receptor Agonist. Journal of Korean Diabetes, 2021, 22, 126-133.	0.1	3
566	Transforming the Care of Patients with Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1590-1600.	2.2	11
567	Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide. Frontiers in Endocrinology, 2021, 12, 645507.	1.5	28

#	Article	IF	Citations
568	New Aspects of Diabetes Research and Therapeutic Development. Pharmacological Reviews, 2021, 73, 1001-1015.	7.1	10
569	Canadian Stroke Best Practice Recommendations: Secondary Prevention of Stroke Update 2020. Canadian Journal of Neurological Sciences, 2022, 49, 315-337.	0.3	57
570	The Johns Hopkins Ciccarone Center's expanded â€˜ABC's approach to highlight 2020 updates in cardiovascular disease prevention. American Journal of Preventive Cardiology, 2021, 6, 100181.	1.3	0
572	Evidence-based use of newer agents in type 2 diabetes. Journal of Prescribing Practice, 2021, 3, 224-234.	0.1	1
573	Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial. Nature Medicine, 2021, 27, 1079-1087.	15.2	62
574	How to fill the GAPS-I in secondary prevention: application of a strategy based on GLP1 analogues, antithrombotic agents, PCSK9 inhibitors, SGLT2 inhibitors and immunomodulators. Panminerva Medica, 2022, 64, .	0.2	4
575	Lipid effects of glucagon-like peptide 1 receptor analogs. Current Opinion in Lipidology, 2021, 32, 191-199.	1.2	13
576	Optimal medical therapy after coronary artery bypass grafting: a primer for surgeons. Current Opinion in Cardiology, 2021, 36, 609-615.	0.8	6
577	Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study. Journal of the American Heart Association, 2021, 10, e019356.	1.6	20
578	Treating heart failure in patients with diabetes: The view of the cardiologist. Diabetes Research and Clinical Practice, 2021, 176, 108852.	1.1	2
579	Changes in body mass index, glycosylated hemoglobin <scp>A1C</scp>, blood pressure, and <scp>LDL</scp>â€cholesterol among type 2 diabetes patients in <scp>Malaysia</scp>: A populationâ€based longitudinal study. Journal of Diabetes, 2021, 13, 915-929.	0.8	4
580	Obesity and GLP-1. Minerva Endocrinology, 2021, 46, 168-176.	0.6	14
581	Management of Kidney Failure in Patients with Diabetes Mellitus: What Are the Best Options?. Journal of Clinical Medicine, 2021, 10, 2943.	1.0	4
582	Cardiovascular Outcome Trials with Glucose-Lowering Drugs. Current Cardiology Reports, 2021, 23, 75.	1.3	6
583	Exercise, Pharmaceutical Therapies and Type 2 Diabetes: Looking beyond Glycemic Control to Whole Body Health and Function. Translational Medicine and Exercise Prescription, 0, , 33-42.	0.0	4
584	What Is an L-Cell and How Do We Study the Secretory Mechanisms of the L-Cell?. Frontiers in Endocrinology, 2021, 12, 694284.	1.5	22
585	Economic Impact of COVID-19 Lockdown on Italian NHS: Focus on Diabetes Mellitus. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 503-518.	0.7	4
586	The effects of antidiabetic agents on heart failure. Netherlands Heart Journal, 2022, 30, 65-75.	0.3	2

#	Article	IF	Citations
587	Using adjuvant pharmacotherapy in the treatment of type 1 diabetes. Expert Opinion on Pharmacotherapy, 2021, 22, 2143-2148.	0.9	4
588	Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, , .	1.4	6
589	Permission to prescribe: do cardiologists need permission to prescribe diabetes medications that afford cardiovascular benefit?. Current Opinion in Cardiology, 2021, 36, 672-681.	0.8	9
590	The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in TypeÂ2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics. Diabetes Therapy, 2021, 12, 1929-1946.	1.2	5
591	Major adverse cardiovascular and limb events in patients with diabetes treated with GLP-1 receptor agonists vs DPP-4 inhibitors. Diabetologia, 2021, 64, 1949-1962.	2.9	29
592	An Overview of Similarities and Differences in Metabolic Actions and Effects of Central Nervous System Between Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) and Sodium Glucose Co-Transporter-2 Inhibitors (SGLT-2is). Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 2955-2972.	1.1	8
593	Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic. Revista Clínica Espanõla, 2021, , .	0.3	1
594	Effect of dulaglutide 3.0 and 4.5Âmg on weight in patients with type 2 diabetes: Exploratory analyses of ‹scp›AWARD‹/scp›â€‘11. Diabetes, Obesity and Metabolism, 2021, 23, 2242-2250.	2.2	23
595	Treatment options following metformin in primary prevention populations with type 2 diabetes: which is the right road to take?. Expert Review of Clinical Pharmacology, 2021, 14, 1189-1192.	1.3	8
596	2021 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association. Diabetes and Metabolism Journal, 2021, 45, 461-481.	1.8	146
597	Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists. Metabolism: Clinical and Experimental, 2021, 120, 154799.	1.5	32
598	Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?. Diabetology and Metabolic Syndrome, 2021, 13, 81.	1.2	7
599	Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. Circulation, 2021, 144, 74-84.	1.6	34
600	Combined medical strategies for the management of type 2 diabetes mellitus and obesity in adults. Expert Opinion on Pharmacotherapy, 2021, 22, 1-22.	0.9	2
601	Pharmacist intervention lowers HgbA1c in diabetic patients regardless of HIV status. Journal of Pharmacy Practice and Research, 2021, 51, 307-313.	0.5	1
602	Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus. Journal of the American Heart Association, 2021, 10, e021084.	1.6	35
603	The benefit of GLP-1RA in different age groups in the cardiovascular outcome trials. Diabetes Research and Clinical Practice, 2021, 177, 108878.	1.1	0
604	GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials. Diabetes Research and Clinical Practice, 2021, 177, 108921.	1.1	10

#	Article	IF	Citations
605	Comparison of the clinical effect of empagliflozin on glycemic and non-glycemic parameters in Japanese patients with type 2 diabetes and cardiovascular disease treated with or without baseline metformin. Cardiovascular Diabetology, 2021, 20, 160.	2.7	2
606	Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 549-556.	1.4	14
607	Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs). Diabetes Therapy, 2021, 12, 2133-2147.	1.2	20
608	Glucagon-Like PeptideÂ1 Receptor Agonist Usage in TypeÂ2 Diabetes in Primary Care for the UK and Beyond: A Narrative Review. Diabetes Therapy, 2021, 12, 2267-2288.	1.2	5
609	Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care. Drugs, 2021, 81, 1373-1379.	4.9	13
610	Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients. Medicine (United) Tj ETQq1 1 0.784314 rgBT /O	0.7	15
611	Pharmacological secondary prevention of MI. The Prescriber, 2021, 32, 13-20.	0.1	0
612	Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE). Archivos De Cardiologia De Mexico, 2021, 92, .	0.1	4
613	Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease?. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 1171-1188.	2.6	17
614	Management of type 2 diabetes in chronic kidney disease. BMJ Open Diabetes Research and Care, 2021, 9, e002300.	1.2	12
616	Effect of Liraglutide on Arterial Inflammation Assessed as [¹⁸ F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Circulation: Cardiovascular Imaging, 2021, 14, e012174.	1.3	18
617	How glucagon-like peptide 1 receptor agonists work. Endocrine Connections, 2021, 10, R200-R212.	0.8	17
618	(Type 2 diabetes and heart failure - how to optimize cooperation of cardiologist and diabetologist). Cor Et Vasa, 2021, 63, 373-377.	0.1	2
619	SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet, The, 2021, 398, 262-276.	6.3	222
620	Favorable Effects of GLP-1 Receptor Agonist against Pancreatic Î²-Cell Glucose Toxicity and the Development of Arteriosclerosis: â€œThe Earlier, the Betterâ€•in Therapy with Incretin-Based Medicine. International Journal of Molecular Sciences, 2021, 22, 7917.	1.8	15
621	CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovascular Diabetology, 2021, 20, 154.	2.7	111
622	2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke, 2021, 52, e364-e467.	1.0	1,123
623	When Inappropriate Use of Insulin is Dangerous: The Utility of C-Peptide Assay in the Era of Cardioprotective Antidiabetic Drugs. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2021, Volume 14, 3517-3521.	1.1	4

#	Article	IF	Citations
625	What Is the Mechanism Driving the Reduction of Cardiovascular Events from Glucagon-like Peptide-1 Receptor Agonists?â€"A Mini Review. Molecules, 2021, 26, 4822.	1.7	10
626	Management of Obesity in CardiovascularÂPractice. Journal of the American College of Cardiology, 2021, 78, 513-531.	1.2	36
627	Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 3257-3270.	1.1	7
628	Dulaglutide for erectile dysfunction in type 2 diabetes. Lancet Diabetes and Endocrinology,the, 2021, 9, 472-473.	5.5	1
629	Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. Cardiovascular Research, 2022, 118, 2231-2252.	1.8	23
630	Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors. Diabetes Therapy, 2021, 12, 2677-2690.	1.2	1
631	Genetically Predicted Glucose-Dependent Insulinotropic Polypeptide (GIP) Levels and Cardiovascular Disease Risk Are Driven by Distinct Causal Variants in the GIPR Region. Diabetes, 2021, 70, 2706-2719.	0.3	12
632	Switching From Daily DPP-4 Inhibitor to Once-Weekly GLP-1 Receptor Activator Dulaglutide Significantly Ameliorates Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Mellitus: A Retrospective Observational Study. Frontiers in Endocrinology, 2021, 12, 714447.	1.5	2
633	Cardiovascular and renal disease manifestation and healthcare resource utilization in patients on firstâ€line oral therapy for type 2 diabetes: A claimsâ€based observational cohort study. Diabetes, Obesity and Metabolism, 2021, 23, 2741-2751.	2.2	4
634	Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?. Expert Opinion on Pharmacotherapy, 2021, 22, 1-13.	0.9	2
635	Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE. Diagnostics, 2021, 11, 1431.	1.3	5
636	Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 484-490.	5.5	17
637	The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 29-38.	1.8	82
638	Effect of glucagonâ€like peptideâ€1 receptor agonists in subjects with type 2 diabetes mellitus: A metaâ€analysis. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 1650-1658.	0.7	4
639	New Antidiabetes Medications and Their Cardiovascular and Renal Benefits. Cardiology Clinics, 2021, 39, 335-351.	0.9	10
640	Cardiovascular Outcomes Trials of Incretin-Based Therapies. Diabetes Spectrum, 2021, 34, 217-224.	0.4	0
641	Cardiovascular disease in diabetes, beyond glucose. Cell Metabolism, 2021, 33, 1519-1545.	7.2	87
642	The Aggressive Diabetic Kidney Disease in Youth-Onset Type 2 Diabetes: Pathogenetic Mechanisms and Potential Therapies. Medicina (Lithuania), 2021, 57, 868.	0.8	23

#	Article	IF	Citations
643	Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2539-2546.	1.1	17
644	Antihyperglycemic Algorithms for Type 2 Diabetes: Focus on Nonglycemic Outcomes. Diabetes Spectrum, 2021, 34, 248-256.	0.4	1
645	Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the <scp>LIRAFLAME</scp> randomized <scp>placeboâ€controlled</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 2651-2659.	2.2	7
646	Communication approaches to enhance patient motivation and adherence in cardiovascular disease prevention. Clinical Cardiology, 2021, 44, 1199-1207.	0.7	13
647	Medical and Surgical Obesity Treatments and Atherosclerosis: Mechanisms beyond Typical Risk Factors. Current Atherosclerosis Reports, 2021, 23, 60.	2.0	3
648	Cardiovascular Disease in Patients with Diabetes: a Comparison of Professional Society Guidelines. Current Diabetes Reviews, 2021, 17, .	0.6	0
649	Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Cohort Study. Diabetes Care, 2021, 44, 2293-2301.	4.3	23
650	Reduction in GLP-1 secretory capacity may be a novel independent risk factor of coronary artery stenosis. Scientific Reports, 2021, 11, 15578.	1.6	0
651	Novel approaches to pharmacological management of type 2 diabetes in Japan. Expert Opinion on Pharmacotherapy, 2021, 22, 2235-2249.	0.9	2
652	Clinical Phenotypes in Patients With Type 2 Diabetes Mellitus: Characteristics, Cardiovascular Outcomes and Treatment Strategies. Current Heart Failure Reports, 2021, 18, 253-263.	1.3	6
653	Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND. Cardiovascular Diabetology, 2021, 20, 194.	2.7	29
654	Usefulness of Glucagon-Like Peptide-1 Receptor Agonists to Reduce Adverse Cardiovascular Disease Events in Patients with Type 2 Diabetes Mellitus. American Journal of Cardiology, 2021, 154, 48-53.	0.7	7
655	Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial. BMJ Open Diabetes Research and Care, 2021, 9, e002395.	1.2	14
656	Pathophysiologic Approach to Type 2 Diabetes Management: One Centre Experience 1980â€“2020. , 0, , .		4
657	GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovascular Diabetology, 2021, 20, 189.	2.7	104
658	Incretinâ€Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes. Clinical Pharmacology and Therapeutics, 2022, 111, 272-282.	2.3	7
659	An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy, 2022, 23, 29-42.	0.9	4
660	Identification of VCAN as Hub Gene for Diabetic Kidney Disease Immune Injury Using Integrated Bioinformatics Analysis. Frontiers in Physiology, 2021, 12, 651690.	1.3	7

#	Article	IF	Citations
661	Advances in Pharmacotherapeutics, Metabolic Surgery, and Technology for Diabetes. Endocrinology and Metabolism Clinics of North America, 2021, 50, 457-474.	1.2	1
662	Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the <scp>ADJUNCT ONE</scp> and <scp>ADJUNCT TWO</scp> randomized controlled trials. Diabetes, Obesity and Metabolism, 2021, 23, 2752-2762.	2.2	16
663	Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study. Journal of Diabetes and Its Complications, 2021, 35, 107972.	1.2	14
664	Rationale and pathways forward in the implementation of coronary artery calcium-based enrichment of randomized trials. American Heart Journal, 2022, 243, 54-65.	1.2	3
665	Primary care management of type 2 diabetes: a comparison of the efficacy and safety of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Postgraduate Medicine, 2021, 133, 1-11.	0.9	3
666	A Comprehensive Cardiovascular-Renal-Metabolic Risk Reduction Approach to Patients with Type 2 Diabetes Mellitus. American Journal of Medicine, 2021, 134, 1076-1084.	0.6	3
667	Immediate Glucose-Lowering Effect After the First Administration of Dulaglutide: A Retrospective, Single-Center, Observational Study. Diabetes Therapy, 2021, 12, 2873-2889.	1.2	1
668	Cardiovascular Risk/Disease in Type 2 Diabetes Mellitus. , 0, , .		4
669	Prevention of Diabetes Macrovascular Complications and Heart Failure. Endocrinology and Metabolism Clinics of North America, 2021, 50, 415-430.	1.2	3
670	Recent developments in <scp>GLPâ€1RA</scp> therapy: A review of the latest evidence of efficacy and safety and differences within the class. Diabetes, Obesity and Metabolism, 2021, 23, 30-39.	2.2	9
671	Cardiovascular risk factors early in the course of treatment in people with type 2 diabetes without established cardiovascular disease: A populationâ€based observational retrospective cohort study. Diabetic Medicine, 2022, 39, e14697.	1.2	4
673	Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study. BMJ Open, 2021, 11, e051549.	0.8	10
674	Drug utilisation study of antidiabetic medication during 2012â€2019 in Romania. International Journal of Clinical Practice, 2021, 75, e14770.	0.8	4
675	Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data. Annals of Translational Medicine, 2021, 9, 1482-1482.	0.7	7
676	Understanding the place for <scp>GLPâ€1RA</scp> therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection. Diabetes, Obesity and Metabolism, 2021, 23, 40-52.	2.2	17
677	Management of Cardiometabolic Complications in Patients With Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology, 2021, 55, 747-756.	1.1	2
678	Analysis of robustness of the landmark Cardiovascular outcome trials of antidiabetic drugs â€“ A systematic review. Current Diabetes Reviews, 2021, 17, .	0.6	0
679	2021 Consensus Pathway of the TaiwanÂSociety of Cardiology on NovelÂTherapyÂfor Type 2 Diabetes. JACC Asia, 2021, 1, 129-146.	0.5	1

#	Article	IF	Citations
680	Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from the SURE UK Multicentre, Prospective, Observational Study. Diabetes Therapy, 2021, 12, 2891-2905.	1.2	18
682	JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Journal of Cardiac Failure, 2021, 27, 1404-1444.	0.7	60
683	Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by <scp>GLPâ€1RA</scp> treatment: A subgroup analysis from the <scp>FIDELIOâ€DKD</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 125-134.	2.2	41
684	Advances in clinical research in chronic kidney disease. Journal of Translational Internal Medicine, 2021, 9, 146-149.	1.0	6
685	JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Circulation Journal, 2021, 85, 2252-2291.	0.7	80
686	Foregone opportunities? Time-to-treatment intensification among adults with type 2 diabetes and elevated HbA1c on metformin monotherapy, 2009-2018. Canadian Journal of Diabetes, 2021, 46, 238-243.e4.	0.4	2
687	Cardiologist's approach to the diabetic patient: No further delay for a paradigm shift. International Journal of Cardiology, 2021, 338, 248-257.	0.8	1
688	Safety and Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Children and Adolescents with Obesity: AÂMeta-Analysis. Journal of Pediatrics, 2021, 236, 137-147.e13.	0.9	42
689	Major adverse limb events in type 2 diabetes patients receiving glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: A retrospective multi-institutional study. Diabetes Research and Clinical Practice, 2021, 180, 109076.	1.1	14
690	Heart Failure in Type 1 Diabetes: A Complication of Concern? A Narrative Review. Journal of Clinical Medicine, 2021, 10, 4497.	1.0	10
691	Role of diabetes in stroke: Recent advances in pathophysiology and clinical management. Diabetes/Metabolism Research and Reviews, 2022, 38, e3495.	1.7	10
692	Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus. American Heart Journal, 2021, 239, 59-63.	1.2	4
693	Sodiumâ€“Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Annals of Internal Medicine, 2021, 174, 1528-1541.	2.0	52
694	Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence. Cardiovascular Diabetology, 2021, 20, 196.	2.7	28
695	Updated Meta-Analysis of Cardiovascular Outcome Trials Evaluating Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists. American Journal of Cardiology, 2021, 159, 143-146.	0.7	5
696	The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis. Journal of General Internal Medicine, 2022, 37, 415-438.	1.3	13
697	The efficacy and safety of novel classes of glucose-lowering drugs for cardiovascular outcomes: a network meta-analysis of randomised clinical trials. Diabetologia, 2021, 64, 2676-2686.	2.9	44
698	Effect of liraglutide on expression of inflammatory genes in type 2 diabetes. Scientific Reports, 2021, 11, 18522.	1.6	21

#	Article	IF	Citations
699	Antidiabetic drugs and oxidized low-density lipoprotein: A review of anti-atherosclerotic mechanisms. Pharmacological Research, 2021, 172, 105819.	3.1	14
700	Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials. American Heart Journal, 2021, 240, 73-80.	1.2	1
701	Heart failure outcomes and glucagon-like peptide-1 receptor agonists: A systematic review of observational studies. Primary Care Diabetes, 2021, 15, 761-771.	0.9	5
702	Glucose as a modifiable cause of atherosclerotic cardiovascular disease: Insights from type 1 diabetes and transplantation. Atherosclerosis, 2021, 335, 16-22.	0.4	10
703	Glucose-lowering therapy in patients undergoing percutaneous coronary intervention. EuroIntervention, 2021, 17, e618-e630.	1.4	3
704	Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes. Metabolism: Clinical and Experimental, 2021, 123, 154838.	1.5	84
705	Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes and Endocrinology,the, 2021, 9, 653-662.	5.5	437
706	Glucagon-Like Peptide-1 Receptor Agonists and Brain Vascular Function. Heart Lung and Circulation, 2021, 30, 1675-1680.	0.2	2
707	Glucagon-like Peptide-1 Receptor Agonists and New Opportunities in Primary Prevention of Cardiovascular Complications in Patients with Type 2 Diabetes Mellitus. Doctor Ru, 2021, 20, 21-29.	0.1	0
708	SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucoseâ€lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review. Diabetic Medicine, 2021, 38, e14502.	1.2	14
709	Should metformin remain the first-line therapy for treatment of type 2 diabetes?. Therapeutic Advances in Endocrinology and Metabolism, 2021, 12, 204201882098022.	1.4	58
711	Pharmacological treatment of hyperglycemia in type 2 diabetes. Journal of Clinical Investigation, 2021, 131, .	3.9	102
712	Distribution and ultrastructural localization of the glucagon-like peptide-1 receptor (GLP-1R) in the rat brain. Brain Structure and Function, 2021, 226, 225-245.	1.2	20
713	Consensus document: management of heart failure in type 2 diabetes mellitus. Heart Failure Reviews, 2021, 26, 1037-1062.	1.7	3
714	Role of Gliclazide MR in the Management of Type 2 Diabetes: Report of a Symposium on Real-World Evidence and New Perspectives. Diabetes Therapy, 2020, 11, 33-48.	1.2	17
715	Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With TypeÂ2 Diabetes Mellitus: The Retrospective REALISE-DM Study. Diabetes Therapy, 2021, 12, 527-536.	1.2	26
716	Targeting oxidative stress and anti-oxidant defence in diabetic kidney disease. Journal of Nephrology, 2020, 33, 917-929.	0.9	38
717	ESVM Guideline on peripheral arterial disease. Vasa - European Journal of Vascular Medicine, 2019, 48, 1-79.	0.6	110

#	Article	IF	Citations
718	5 Conservative treatment for PAD â€“ Risk factor management. Vasa - European Journal of Vascular Medicine, 2019, 48, 1-12.	0.6	15
721	Safety of injectable semaglutide for type 2 diabetes. Expert Opinion on Drug Safety, 2020, 19, 785-798.	1.0	10
722	Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists. American Journal of Health-System Pharmacy, 2021, 78, 556-567.	0.5	11
723	Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 104-111.	1.4	23
724	Cardiovascular effectiveness of human-based vs. exendin-based glucagon like peptide-1 receptor agonists: a retrospective study in patients with type 2 diabetes. European Journal of Preventive Cardiology, 2021, 28, 22-29.	0.8	12
725	Semaglutide. Cardiology in Review, 2021, 29, 100-108.	0.6	3
726	Association between TNFâ€Î± Gâ€308A (rs1800629) polymorphism and susceptibility to chronic periodontitis and type 2 diabetes mellitus: A metaâ€analysis. Journal of Periodontal Research, 2021, 56, 226-235.	1.4	16
727	Genetics Insights in the Relationship Between Type 2 Diabetes and Coronary Heart Disease. Circulation Research, 2020, 126, 1526-1548.	2.0	58
728	Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-Î±. Journal of Clinical Investigation, 2020, 130, 1392-1404.	3.9	37
729	Diagnosis, Prevention, and Treatment of Cardiovascular Diseases in People With Type 2 Diabetes and Prediabetesã€€â€• A Consensus Statement Jointly From the Japanese Circulation Society and the Japan Diabetes Society â€•. Circulation Journal, 2020, 85, 82-125.	0.7	16
730	Diabetes mellitus type 2 in adults. Diabetes Mellitus, 2020, 23, 4-102.	0.5	16
731	MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?. European Journal of Endocrinology, 2019, 181, R211-R234.	1.9	156
732	2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology, 2020, 25, 4083.	0.4	229
733	2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology, 2020, 25, 4083.	0.4	32
734	Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2020, 42, 467-477.	0.4	3
735	Once-weekly Dulaglutide and Major Cardiovascular Eventsâ€"Results of the REWIND Trial. US Endocrinology, 2019, 15, 65.	0.3	2
736	Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Glucagon-like Peptide-1 Receptor Agonists. US Endocrinology, 2020, 16, 80.	0.3	7
737	Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan. Aging, 2020, 12, 24940-24956.	1.4	20

#	Article	IF	Citations
738	Novel Antidiabetic Agents: Cardiovascular and Safety Outcomes. Current Pharmaceutical Design, 2020, 26, 5911-5932.	0.9	8
739	Pharmacological Management of Diabetes for Reducing Glucose Levels and Cardiovascular Disease Risk: What Evidence in South Asians?. Current Diabetes Reviews, 2020, 17, e122820189511.	0.6	3
740	Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 70-78.	2.2	54
741	Overbasalization: Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin. Clinical Diabetes, 2020, 38, 304-310.	1.2	16
742	HbA1c Change and Diabetic Retinopathy During GLP-1 Receptor Agonist Cardiovascular Outcome Trials: A Meta-analysis and Meta-regression. Diabetes Care, 2021, 44, 290-296.	4.3	49
744	Post-transplant diabetes mellitus and preexisting liver disease - a bidirectional relationship affecting treatment and management. World Journal of Gastroenterology, 2020, 26, 2740-2757.	1.4	14
745	A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans. Endocrinology and Metabolism, 2019, 34, 247.	1.3	64
746	Range of adiposity and cardiorenal syndrome. World Journal of Diabetes, 2020, 11, 322-350.	1.3	13
747	Management of type 2 diabetes: consensus of diabetes organizations. Drugs in Context, 2020, 9, 1-25.	1.0	19
748	Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia. Clinical Medicine Insights: Endocrinology and Diabetes, 2021, 14, 117955142110516.	1.0	6
749	Obesity-Related Glomerulopathy: Clinical Management. Seminars in Nephrology, 2021, 41, 358-370.	0.6	6
750	Decision Points in the Management of Patients with Diabetic Kidney Disease. , 2021, 70, S7-S12.		0
751	Women and Diabetes: Preventing Heart Disease in a New Era of Therapies. European Cardiology Review, 2021, 16, e40.	0.7	9
752	Stroke prevention in diabetes with glucagon-like peptide-1 receptor agonists: A game-changer?. Journal of Diabetes and Its Complications, 2021, 35, 108075.	1.2	0
753	The association between GLP-1 receptor agonist and diabetic ketoacidosis in the FDA adverse event reporting system. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 504-510.	1.1	6
754	Diabetes, Vascular Aging and Stroke: Old Dogs, New Tricks?. Journal of Clinical Medicine, 2021, 10, 4620.	1.0	13
755	A renaissance in the treatment of diabetic kidney disease, hypertension in chronic kidney disease, and beyond. Journal of Osteopathic Medicine, 2021, 122, 55-63.	0.4	2
756	The role of hyperglycaemia in the development of diabetic cardiomyopathy. Archives of Cardiovascular Diseases, 2021, 114, 748-760.	0.7	24

#	Article	IF	Citations
757	Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease. JAMA Internal Medicine, 2021, 181, 1575.	2.6	28
758	Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System. Frontiers in Endocrinology, 2021, 12, 738848.	1.5	36
760	Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat. Journal of Endocrinological Investigation, 2022, 45, 489-495.	1.8	17
762	An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus. Expert Opinion on Drug Safety, 2022, 21, 349-361.	1.0	4
763	Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet, The, 2021, 398, 1811-1824.	6.3	257
764	The adiponectin signalling pathway - A therapeutic target for the cardiac complications of type 2 diabetes?. , 2022, 232, 108008.		19
765	Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression. Cardiovascular Diabetology, 2021, 20, 210.	2.7	31
766	Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. The Cochrane Library, 2021, 2021, CD013650.	1.5	28
769	Association between novel Glucose-Lowering drugs and risk of Asthma: A network Meta-Analysis of cardiorenal outcome trials. Diabetes Research and Clinical Practice, 2022, 183, 109080.	1.1	12
770	One hundred years since insulin discovery: An update on current and future perspectives for pharmacotherapy of diabetes mellitus. British Journal of Clinical Pharmacology, 2022, 88, 1598-1612.	1.1	4
771	Essential Points of Treatment and Examination to Prevent Diabetic Kidney Disease Aggravation. Juntendo Medical Journal, 2019, 65, 529-536.	0.1	0
772	SelecciÃ³n de lo mejor del aÃ±o 2018 en riesgo vascular y rehabilitaciÃ³n cardiaca. REC: CardioClinics, 2019, 54, 44-50.	0.1	0
773	Diabetes management: Beyond hemoglobin A1c. Cleveland Clinic Journal of Medicine, 2019, 86, 595-600.	0.6	3
775	Highlights from the 79th Scientific Sessions of the American Diabetes Association. British Journal of Diabetes, 2019, 19, 147-149.	0.1	0
776	Letter: Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes (Endocrinol Metab 2019; 34:382-9, Han Na Jang) Tj ETQq0 1 0 rgBT /Overlock 1	0.0	0
777	Inflammatory Mechanisms in Diabetic Kidney Disease. , 2020, , 437-455.		0
778	Type of diabetes mellitus: Does it matter to the clinician?. Cleveland Clinic Journal of Medicine, 2020, 87, 100-108.	0.6	6
781	Series: Cardiovascular outcome trials for diabetes drugs Lixisenatide and ELIXA. British Journal of Diabetes, 2020, 20, 52-54.	0.1	0

#	Article	IF	Citations
782	Diabetes medications with cardiovascular protection as we enter a new decade: can SGLT2 inhibitors, long-acting GLP-1 receptor agonists, pioglitazone and metformin complement each other to save lives?. British Journal of Diabetes, 2020, 20, 5-8.	0.1	1
783	GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis. Exploration of Medicine, 2020, 1, 108-123.	1.5	3
786	Severe Visceral Obesity, Fatty Liver and Diabetes after Orchiectomy for Prostate Cancer. Internal Medicine, 2020, 59, 2281-2285.	0.3	1
787	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). Eurasian Heart Journal, 2020, , 6-76.	0.2	6
788	Glucagon-like Peptide-1 Receptor Agonists and Cardioprotective Benefit in Patients with Type 2 Diabetes Without Baseline Metformin: A Systematic Review and Update Meta-analysis. High Blood Pressure and Cardiovascular Prevention, 2021, 28, 605-612.	1.0	5
789	The incretin/glucagon system as a target for pharmacotherapy of obesity. Obesity Reviews, 2022, 23, .	3.1	26
790	Pharmacotherapy for patients with diabetes mellitus. Journal of the Korean Medical Association, 2020, 63, 766-775.	0.1	0
791	Liraglutid in diabetic patients in LEADER study - is there any benefit in patients with heart failure?. Klinicka Farmakologie A Farmacie, 2020, 34, 168-170.	0.1	0
792	Prevention of Heart Failure. Contemporary Cardiology, 2021, , 489-512.	0.0	1
793	A stepwise approach for pharmacists: Cardiovascular risk reduction with novel antihyperglycemic agents in patients with type 2 diabetes and atherosclerotic cardiovascular disease. Canadian Pharmacists Journal, 2021, 154, 30-35.	0.4	0
794	Prevention of Ischemic Stroke. Contemporary Cardiology, 2021, , 581-609.	0.0	0
795	The Association Between Baseline Insulin Treatment and Cardiovascular Events: A Meta-Analysis. Journal of the Endocrine Society, 2021, 5, bvaa193.	0.1	4
796	Is cardioprotection with GLP-1 receptor agonists a class effect?. European Journal of Preventive Cardiology, 2021, 28, 18-21.	0.8	0
797	Diabetes medications with cardiovascular protection: the likelihood of benefit from combination therapy increases further following new evidence during 2020. British Journal of Diabetes, 2020, 20, 85-88.	0.1	4
798	Primary Prevention of Cardiovascular Disease Guidelines. Contemporary Cardiology, 2021, , 653-672.	0.0	0
799	Heart Failure in Diabetes Mellitus: An Updated Review. Current Pharmaceutical Design, 2020, 26, 5933-5952.	0.9	3
800	Glucagon-like Peptide-1 Receptor Agonists. Stroke Revisited, 2021, , 167-177.	0.2	0
801	Standard Pharmacological Treatment of Diabetes Based on the Guidelines. Stroke Revisited, 2021, , 179-187.	0.2	0

#	Article	IF	Citations
802	Dipeptidyl Peptidase-4 Inhibitors. Stroke Revisited, 2021, , 143-154.	0.2	0
803	Targeting the Epicardial Adipose Tissue. Contemporary Cardiology, 2020, , 173-187.	0.0	1
805	Cardiovascular Impact of Newer Diabetes Medications. , 2020, , 735-745.		0
807	Glucagon-like Peptide-1 Receptor Agonists: Limitless Potential. Doctor Ru, 2020, 19, 6-12.	0.1	1
808	What may GLP1 receptor agonists contribute to the treatment of patients with non-alcoholic fatty liver disease?. Revista Espanola De Enfermedades Digestivas, 2020, 112, 587-589.	0.1	0
809	Organoprotective effects of glucagon-like peptide-1 receptor agonists with regard to findings of evidencebased cardiovascular safety studies. Meditsinskiy Sovet, 2020, , 189-197.	0.1	1
810	The role of novel antihyperglycaemic agents in the treatment of Type 2 diabetes: From glycaemic control to cardiovascular protection. Arhiv Za Farmaciju, 2020, 70, 198-223.	0.2	0
811	An updated perspective and pooled analysis of Cardiovascular outcome trials of GLP-1 receptor agonists and SGLT-2 inhibitors. Anatolian Journal of Cardiology, 2020, 25, 61-76.	0.5	1
812	Oral GLP1 Analog: Where Does the Tide Go?. Clinical Medicine Insights: Endocrinology and Diabetes, 2020, 13, 117955142098413.	1.0	6
814	Beneficial Agents for Patients With Type 2 Diabetes and Cardiovascular Disease or Obesity: Utilization in an Era of Accumulating Evidence. Clinical Diabetes, 2020, 38, 176-180.	1.2	0
815	SelecciÃ³n de lo mejor del aÃ±o 2019 en riesgo vascular y rehabilitaciÃ³n cardiaca. REC: CardioClinics, 2020, 55, 18-24.	0.1	0
816	The year in cardiology: cardiovascular prevention. The year in cardiology 2019.. SA Heart Journal, 2020, 17, .	0.0	0
817	Impact of Metabolic Surgery on Type 2 Diabetes Mellitus, Cardiovascular Risk Factors, and Mortality: A Review. Current Hypertension Reviews, 2021, 17, 159-169.	0.5	3
818	Cardiovascular risk profiles: A crossâ€sectional study evaluating the generalizability of the glucagonâ€like peptideâ€1 receptor agonist cardiovascular outcome trials <scp>REWIND</scp>, <scp>LEADER</scp> and <scp>SUSTAIN</scp>â€6 to the realâ€world type 2 diabetes population in the <scp>United Kingdom</scp>. Diabetes, Obesity and Metabolism, 2022, 24, 289-295.	2.2	8
819	Practicable Measurement and Identification of Overbasalization. Clinical Diabetes, 2022, 40, 75-77.	1.2	2
820	The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus. Cardiovascular Drugs and Therapy, 2022, 36, 561-567.	1.3	16
823	Pharmacological therapy and cardiovascular risk reduction for type 2 diabetes. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2020, 66, 1283-1288.	0.3	1
824	Clinical implications of the log linear association between LDL-C lowering and cardiovascular risk reduction: Greatest benefits when LDL-C >100 mg/dl. PLoS ONE, 2020, 15, e0240166.	1.1	2

#	Article	IF	Citations
825	Diabetic Kidney Disease. Nephrology Self-assessment Program: NephSAP, 2020, 19, 110-139.	3.0	1
827	Management of Diabetes Mellitus in Acute and Chronic Cardiorenal Syndromes. , 2021, , 295-313.		0
828	Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combinationâ€"are we exploiting their full potential in a real life setting?. World Journal of Diabetes, 2020, 11, 540-552.	1.3	2
830	Jak postupovat v boji s inzulinovou rezistencÃ-u pacientÅ¯ s DM 2. typu. Vnitrni Lekarstvi, 2020, 66, 4-6.	0.1	1
832	Finding the sweet spot in managing diabetes with coronary artery disease and chronic kidney disease: Pharmacotherapy pearls with a focus on sodium-glucose cotransporter-2 inhibitors. Canadian Family Physician, 2020, 66, 341-346.	0.1	0
833	Chinese Guideline on the Primary Prevention of Cardiovascular Diseases. Cardiology Discovery, 2021, 1, 70-104.	0.6	13
834	Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors. Med, 2021, 2, 1203-1230.	2.2	17
835	Comparing Real-World Effectiveness of Dulaglutide and Insulin as the First Injectable for Patients with TypeÂ2 Diabetes: An Australian Single-Site Retrospective Chart Review. Diabetes Therapy, 2021, 13, 131.	1.2	0
836	Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, PhaseÂI Study. Advances in Therapy, 2022, 39, 488-503.	1.3	4
837	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes and Endocrinology,the, 2022, 10, 24-34.	5.5	40
838	COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting EnzymeÂ2, Mutual Effects and Pharmacotherapy. Frontiers in Endocrinology, 2021, 12, 772865.	1.5	15
839	GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes. Kidney International, 2022, 101, 360-368.	2.6	15
840	Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. Circulation, 2022, 145, 565-574.	1.6	59
841	Optimization of Medication Regimens in Patients with Type 2 Diabetes and Clinical Atherosclerotic Cardiovascular Disease. Pharmacy (Basel, Switzerland), 2021, 9, 186.	0.6	2
842	Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2021, 385, 2105-2107.	13.9	2
843	Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial. Frontiers in Endocrinology, 2021, 12, 790405.	1.5	16
844	Clinical relevance of recent outcome trials with antidiabetic drugs. Practical Diabetes, 2021, 38, 3-6.	0.1	0
845	Glucagon-like peptide-1 receptor agonists and sodiumâ^'glucose cotransporter 2 inhibitors for cardiovascular and renal protection: A treatment approach far beyond their glucose-lowering effect. European Journal of Internal Medicine, 2022, 96, 26-33.	1.0	7

#	Article	IF	Citations
846	Association between body mass index and survival in Taiwanese heart failure patients with and without diabetes mellitus. Medicine (United States), 2021, 100, e28114.	0.4	1
847	Inercia terapÃ©utica en el control glucÃ©mico segÃºn objetivos individualizados en una cohorte de pacientes con diabetes de tipo 2: resultados del estudio CONCARDIA2. Endocrinologia, Diabetes Y NutriciÃ“n, 2021, , .	0.1	0
848	Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond. Heart Failure Reviews, 2023, 28, 667-681.	1.7	14
849	Updated network meta-analysis assessing the relative efficacy of 13 GLP-1 RA and SGLT2 inhibitor interventions on cardiorenal and mortality outcomes in type 2 diabetes. European Journal of Clinical Pharmacology, 2021, , 1.	0.8	0
850	Comparative Effectiveness of SGLT2i Versus GLP1-RA on Cardiovascular Outcomes in Routine Clinical Practice. SSRN Electronic Journal, 0, , .	0.4	0
851	Changing the Concept: From the Traditional Glucose-centric to the New Cardiorenal-metabolic Approach for the Treatment of Type 2 Diabetes. European Endocrinology, 2021, 17, 92.	0.8	1
852	Century of Evolution of Non-Insulin Therapeutic Options in Management of Diabetes. Journal of Diabetes Mellitus, 2021, 11, 305-316.	0.1	1
853	GLP-1a: Going beyond Traditional Use. International Journal of Molecular Sciences, 2022, 23, 739.	1.8	31
854	Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the <scp>REWIND</scp> randomized trial. Diabetes, Obesity and Metabolism, 2022, 24, 704-712.	2.2	4
855	<scp>Glucagonâ€like peptide</scp>â€1 receptor agonists as adjunctive treatment for type 1 diabetes: Renewed opportunities through tailored approaches?. Diabetes, Obesity and Metabolism, 2022, 24, 769-787.	2.2	12
857	The Enhanced Cardiac Outcome of Conjugated SGLT2 Inhibitors and GLP-1RA Therapy in Diabetic Patients. Current Cardiology Reports, 2022, , .	1.3	1
858	The molecular link between oxidative stress, insulin resistance, and type 2 diabetes: A target for new therapies against cardiovascular diseases. Current Opinion in Pharmacology, 2022, 62, 85-96.	1.7	51
859	HÃmoglobin A 1c: Die heutige Rolle fÃ¼r die therapeutische Entscheidung. , 0, , .		0
860	Typ-2-Diabetes: Wie Endpunktstudien die Therapie verÃndern. , 0, , .		0
861	Herzinsuffizienz als KomorbiditÃt: Kardioprotektion ist mÃ¶glich. , 0, , .		0
862	Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis. Cardiology Journal, 2020, , .	0.5	1
863	What Have We Learnt from Cardiovascular Outcome Studies of New Anti-diabetic Therapies in Last Decade?. Current Research in Diabetes & Obesity Journal, 2020, 13, .	0.1	0
864	Glycaemic Control in Diabetes. Handbook of Experimental Pharmacology, 2021, , 47-71.	0.9	1

#	Article	IF	Citations
865	Diabetes and cardiovascular outcome trials: a review with a focus on the use of glucagon-like peptide-1 receptor agonists in clinical practice. South African General Practitioner, 2021, 2, 100-105.	0.0	0
866	Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists. Advances in Chronic Kidney Disease, 2021, 28, 337-346.	0.6	3
867	Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. Advances in Chronic Kidney Disease, 2021, 28, 347-360.	0.6	5
868	Novel Glucose-Lowering Therapies in the Setting of Solid Organ Transplantation. Advances in Chronic Kidney Disease, 2021, 28, 361-370.	0.6	1
869	Strategies for the Management of Type 2 Diabetes. , 2022, , 2046-2052.		0
870	Overcoming Barriers to Implementing New Therapies for Diabetic Kidney Disease: Lessons Learned. Advances in Chronic Kidney Disease, 2021, 28, 318-327.	0.6	9
871	The effect of modern hypoglycemic therapy on the course of chronic kidney disease in patients with type 2 diabetes mellitus. MÃ¬Å¾narodnij EndokrinologÃ¬Änij Å½urnal, 2021, 17, 624-632.	0.1	0
872	Glucose-dependent insulinotropic polypeptide and tissue inflammation: Implications for atherogenic cardiovascular disease. European Journal of Inflammation, 2022, 20, 205873922110704.	0.2	0
873	Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension. Pulmonary Circulation, 2022, 12, e12028.	0.8	8
874	Three-step matching algorithm to enhance between-group comparability and minimize confounding in comparative effectiveness studies. Scientific Reports, 2022, 12, 214.	1.6	0
875	Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study. Scientific Reports, 2022, 12, 154.	1.6	3
876	Putting it All Together: Practical Approach to the Patient with Diabetic Kidney Disease. , 2022, , 637-659.		1
877	Incidence and Predictors of Primary Nonadherence to Sodium Glucose Co-transporter 2 Inhibitors and Glucagon-Like Peptide 1 Agonists in a Large Integrated Healthcare System. Journal of General Internal Medicine, 2022, 37, 3562-3569.	1.3	7
878	Cardiovascular Profile of Patients with Type 2 Diabetes in France Based on REWIND CVOT Inclusion Criteria: A Real-World Retrospective Study. Diabetes Therapy, 2022, 13, 287-299.	1.2	0
879	Therapeutic Advances in Diabetic Nephropathy. Journal of Clinical Medicine, 2022, 11, 378.	1.0	49
880	Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice. International Journal of Cardiology, 2022, 352, 172-179.	0.8	13
881	Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study. Diabetology and Metabolic Syndrome, 2022, 14, 5.	1.2	0
884	The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia. Current Atherosclerosis Reports, 2022, 24, 13-21.	2.0	7

#	Article	IF	Citations
885	Saudi Consensus for GLP-1 RAs Switching Guidance: Consensus Report. International Journal of Clinical Medicine, 2022, 13, 22-35.	0.1	1
886	Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. Circulation, 2022, 145, CIR0000000000001040.	1.6	193
887	A Specific High-Protein Weight Loss Program Does Not Impair Renal Function in Patients Who Are Overweight/Obese. Nutrients, 2022, 14, 384.	1.7	4
889	Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice. Diabetes Therapy, 2022, 13, 225-240.	1.2	4
890	HbA1c Reduction in Dulaglutide-Treated Patients Irrespective of Duration of Diabetes, Microvascular Disease, and BMI: A Post Hoc Analysis From the REWIND Trial. Diabetes Care, 2022, , .	4.3	4
891	EstÃ¡ndares SEA 2022 para el control global del riesgo cardiovascular. ClÃnica E InvestigaciÃ³n En Arteriosclerosis, 2022, 34, 130-179.	0.4	11
892	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2022, 36, 108101.	1.2	23
893	The PRIME Type 2 Diabetes Model: a novel, patient-level model for estimating long-term clinical and cost outcomes in patients with type 2 diabetes mellitus. Journal of Medical Economics, 2022, 25, 393-402.	1.0	7
894	Informing and Empowering Patients and Clinicians to Make Evidence-Supported Outcome-Based Decisions in Relation to SGLT2 Inhibitor Therapies: The Use of the Novel Years of Drug administration (YoDa) Concept. Clinical Drug Investigation, 2022, 42, 113-125.	1.1	2
895	Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia. Lancet Diabetes and Endocrinology,the, 2022, 10, 142-148.	5.5	7
896	Impact of socioeconomic position on initiation of SGLT-2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes â€“ a Danish nationwide observational study. Lancet Regional Health - Europe, The, 2022, 14, 100308.	3.0	17
897	Targeting Epicardial Fat in Obesity and Diabetes Pharmacotherapy. Handbook of Experimental Pharmacology, 2022, , 93-108.	0.9	3
898	The gut hormone glucose-dependent insulinotropic polypeptide is downregulated in response to myocardial injury. Cardiovascular Diabetology, 2022, 21, 18.	2.7	0
899	GLP-1 receptor agonists and cardiovascular outcomes in patients with type 2 diabetes: Clinical evidence and best practice. Journal of the American Association of Nurse Practitioners, 2022, 34, 418-440.	0.5	2
900	Redefining diabetes mellitus treatments according to different mechanisms beyond hypoglycaemic effect. Heart Failure Reviews, 2022, , .	1.7	0
901	Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2022, Volume 15, 281-295.	1.1	35
902	Physiologic Insulin Resensitization as a Treatment Modality for Insulin Resistance Pathophysiology. International Journal of Molecular Sciences, 2022, 23, 1884.	1.8	5
903	Diabetes mellitus and cardiovascular risk: an update of the recommendations of the Diabetes and Cardiovascular Disease Working Group of the Spanish Society of Diabetes (SED, 2021). ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2022, , .	0.1	0

#	Article	IF	Citations
904	Cardiovascular Effectiveness of Sodiumâ€Glucose Cotransporter 2 Inhibitors and Glucagonâ€Like Peptideâ€1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure. Journal of the American Heart Association, 2022, 11, e022376.	1.6	14
905	Effects of glucagonâ€like peptideâ€1 receptor agonists on cardiovascular and renal outcomes: A <scp>metaâ€analysis</scp> and <scp>metaâ€regression</scp> analysis. Diabetes, Obesity and Metabolism, 2022, 24, 1029-1037.	2.2	18
906	Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease. Journal of Personalized Medicine, 2022, 12, 223.	1.1	5
907	EGCG-derived polymeric oxidation products enhance insulin sensitivity in db/db mice. Redox Biology, 2022, 51, 102259.	3.9	9
908	Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US. JAMA Health Forum, 2021, 2, e214182.	1.0	58
909	CAC for Risk Stratification Among Individuals With Hypertriglyceridemia Free of Clinical Atherosclerotic Cardiovascular Disease. JACC: Cardiovascular Imaging, 2022, 15, 641-651.	2.3	11
910	Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER. Circulation, 2022, 145, 575-585.	1.6	88
911	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetesâ€”2022. Diabetes Care, 2022, 45, S144-S174.	4.3	282
912	Compliance with Prescription Guidelines for Glucose-Lowering Therapies According to Renal Function: Real-Life Study in Inpatients of Internal Medicine, Endocrinology and Cardiology Units. Medicina (Lithuania), 2021, 57, 1376.	0.8	1
913	Pharmacotherapy to delay the progression of diabetic kidney disease in people with type 2 diabetes: past, present and future. Therapeutic Advances in Endocrinology and Metabolism, 2022, 13, 204201882210816.	1.4	10
914	Cardiovascular effects of GLP-1 receptor agonism. Advances in Pharmacology, 2022, , 213-254.	1.2	5
916	Efficacy of Dulaglutide in a Patient With Type 2 Diabetes, High Cardiovascular Risk, and HIV: A Case Report. Frontiers in Endocrinology, 2022, 13, 847778.	1.5	2
917	Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations. Diabetes Therapy, 2022, 13, 389-421.	1.2	8
918	Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus. Endocrinology and Metabolism, 2022, 37, 26-37.	1.3	20
919	2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care. Primary Care Diabetes, 2022, 16, 223-244.	0.9	15
920	The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal. Diabetology and Metabolic Syndrome, 2022, 14, 32.	1.2	4
921	Low Use of Guideline-recommended Cardiorenal Protective Antihyperglycemic Agents in Primary Care: A Cross-sectional Study of Adults With Type 2 Diabetes. Canadian Journal of Diabetes, 2022, 46, 487-494.	0.4	4
922	Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nature Medicine, 2022, 28, 591-598.	15.2	139

#	Article	IF	Citations
923	Diabetes mellitus and heart failure: an update on pathophysiology and therapy. Minerva Cardiology and Angiology, 2022, , .	0.4	5
925	Contemporary Medical Therapies for Patients with Peripheral Artery Disease and Concomitant Type 2 Diabetes Mellitus: a Review of Current Evidence. Current Cardiology Reports, 2022, 24, 567-576.	1.3	2
926	Gastrointestinal Incretinsâ€"Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Diseaseâ€"State of the Art. Biology, 2022, 11, 288.	1.3	9
927	Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis. Minerva Cardiology and Angiology, 2023, 71, .	0.4	6
928	Exenatide Once Weekly for Management of Type 2 Diabetes: A Review. Clinical Pharmacology: Advances and Applications, 2022, Volume 14, 19-26.	0.8	2
929	Time-series analysis of recent antihyperglycemic medication prescribing trends for a diverse sample of Medicare enrollees with type 2 diabetes mellitus in an integrated health system. American Journal of Health-System Pharmacy, 2022, 79, 950-959.	0.5	2
930	Comparison of Sodiumâ€"Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials. Journal of Cardiovascular Pharmacology, 2022, 79, 281-288.	0.8	15
931	Diabetes Mellitus and the Heart. Experimental and Clinical Endocrinology and Diabetes, 2022, , .	0.6	1
932	Preventing allâ€cause hospitalizations in type 2 diabetes with sodiumâ€glucose cotransporterâ€2 inhibitors and <scp>glucagonâ€like peptide</scp>â€1 receptor agonists: A narrative review and proposed clinical approach. Diabetes, Obesity and Metabolism, 2022, 24, 969-982.	2.2	5
934	Premature Death in Kidney Transplant Recipients: The Time for Trials is Now. Journal of the American Society of Nephrology: JASN, 2022, 33, 665-673.	3.0	4
935	Renal outcomes associated with glucose-lowering agents: Systematic review and meta-analysis of randomized outcome trials. European Journal of Internal Medicine, 2022, 97, 78-85.	1.0	2
936	GLP-1 Receptor Agonists and Coronary Arteries: From Mechanisms to Events. Frontiers in Pharmacology, 2022, 13, 856111.	1.6	8
937	Effects of GLP-1RAs on cardiovascular outcomes in patients with type 2 diabetes mellitus: review of real-world data on target populations from diabetes registry in Russian Federation. Diabetes Mellitus, 2022, 25, 61-71.	0.5	2
938	Implementation of Cardiometabolic Centers and Training Programs. Current Diabetes Reports, 2022, , 1.	1.7	0
939	GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions. Kidney Research and Clinical Practice, 2022, 41, 136-149.	0.9	12
940	Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease. Diabetes, Obesity and Metabolism, 2022, 24, 1288-1299.	2.2	14
941	Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction. Cardiac Failure Review, 2022, 8, e10.	1.2	0
942	Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease. JAMA Network Open, 2022, 5, e221169.	2.8	24

#	Article	IF	Citations
943	GLP-1RAs for Ischemic Stroke Prevention in Patients With Type 2 Diabetes Without Established Atherosclerotic Cardiovascular Disease. Diabetes Care, 2022, 45, 1184-1192.	4.3	13
944	Diabetic Heart Failure with Preserved Left Ventricular Ejection Fraction: Review of Current Pharmacotherapy. Journal of Diabetes Research, 2022, 2022, 1-10.	1.0	1
945	Review article: role of glucagonâ€like peptideâ€1 receptor agonists in nonâ€alcoholic steatohepatitis, obesity and diabetesâ€"what hepatologists need to know. Alimentary Pharmacology and Therapeutics, 2022, 55, 944-959.	1.9	17
946	Retrospective evaluation of microalbuminuria and GFR levels of diabetic patients taking DPP-4 Inhibitor, GLP-1 Analog, or SGLT-2 Inhibitor. Turkish Journal of Internal Medicine, 0, , .	0.3	0
947	Tirzepatide for diabetes: on track to SURPASS current therapy. Nature Medicine, 2022, 28, 450-451.	15.2	4
948	Current Status of Low-Density Lipoprotein Cholesterol Target Achievement in Patients with Type 2 Diabetes Mellitus in Korea Compared with Recent Guidelines. Diabetes and Metabolism Journal, 2022, 46, 464-475.	1.8	8
949	A Horse, a Jockey, and a Therapeutic Dilemma: Choosing the Best Option for a Patient with Diabetes and Coronary Artery Disease. American Journal of Cardiovascular Drugs, 2022, 22, 357-361.	1.0	4
951	Cardiorenal outcomes with ertugliflozin assessed according to baseline glucoseâ€lowering agent: An analysis from <scp>VERTIS CV</scp>. Diabetes, Obesity and Metabolism, 2022, , .	2.2	5
952	Protecting the Kidneys: Update on Therapies to Treat Diabetic Nephropathy. Clinical Diabetes, 2022, 40, 305-311.	1.2	1
953	Comparable Cardiorenal Benefits of SGLT2 Inhibitors and GLP-1RAs in Asian and White Populations: An Updated Meta-analysis of Results From Randomized Outcome Trials. Diabetes Care, 2022, 45, 1007-1012.	4.3	4
954	The Impact of Novel Anti-Diabetic Medications on CV Outcomes: A New Therapeutic Horizon for Diabetic and Non-Diabetic Cardiac Patients. Journal of Clinical Medicine, 2022, 11, 1904.	1.0	4
955	Epicardial adipose tissue in contemporary cardiology. Nature Reviews Cardiology, 2022, 19, 593-606.	6.1	160
956	Benefits of GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists for Stroke Reduction in Type 2 Diabetes: A Call to Action for Neurologists. Stroke, 2022, 53, 1813-1822.	1.0	18
957	Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients with Type 2 Diabetes. Epidemiology, 2022, Publish Ahead of Print, .	1.2	6
958	Predictors of Clinical Inertia and Type 2 Diabetes: Assessment of Primary Care Physicians and Their Patients. International Journal of Environmental Research and Public Health, 2022, 19, 4436.	1.2	3
959	The cardiovascular benefits of GLP1-RAs are related to their positive effect on glycemic control: A meta-regression analysis. Diabetes Research and Clinical Practice, 2022, 186, 109824.	1.1	5
960	Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure. Cardiovascular Diabetology, 2022, 21, 51.	2.7	7
961	Adherence of physicians to evidence-based management guidelines for treating type 2 diabetes and atherosclerotic cardiovascular disease in Ajman, United Arab Emirates. , 2022, 23, 70.		1

#	Article	IF	Citations
962	Obesityâ€related glomerulopathy: Current approaches and future perspectives. Obesity Reviews, 2022, 23, e13450.	3.1	26
963	Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes. Primary Care Diabetes, 2022, , .	0.9	1
964	A Glucagon-like Peptide 1 Analog Protects Mitochondria and Attenuates Hypoxiaâ€“Reoxygenation Injury in Cultured Cardiomyocytes. Journal of Cardiovascular Pharmacology, 2022, 79, 568-576.	0.8	5
965	Knowledge Domain and Emerging Trends of Glucagon-Like Peptide 1 Receptor Agonists in Cardiovascular Research: A Bibliometric Analysis. Current Problems in Cardiology, 2023, 48, 101194.	1.1	5
966	Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes. Diabetes Research and Clinical Practice, 2022, 187, 109855.	1.1	4
967	Glucose-lowering drugs, cognition, and dementia: The clinical evidence. Neuroscience and Biobehavioral Reviews, 2022, 137, 104654.	2.9	7
968	Why do SGLT2 Inhibitors Act as Cardio-renal Protective even in Non-diabetics?. Japanese Journal of Clinical Pharmacology and Therapeutics, 2021, 52, 157-164.	0.1	0
969	Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Cardiovascular Disease: The Past, Present, and Future. American Journal of Cardiovascular Drugs, 2022, 22, 363-383.	1.0	7
970	Nephropathy and chronic renal insufficiency. Journal of Gerontology and Geriatrics, 2021, 69, 262-264.	0.2	0
971	Maximum body mass index before onset of type 2 diabetes is independently associated with advanced diabetic complications. BMJ Open Diabetes Research and Care, 2021, 9, e002466.	1.2	2
972	Optimal Type 2 Diabetes Mellitus Management and Active Ageing. Endocrines, 2021, 2, 523-539.	0.4	1
973	Three new categories of hypoglycaemic agents and various cardiovascular diseases: A metaâ€analysis. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 636-642.	0.7	3
974	Interpretation of clinical trials on the cardiovascular effects of hypoglycemic drugs in people with type 2 diabetes. EndocrinologÃa Diabetes Y NutriciÃ³n (English Ed), 2021, 68, 741-750.	0.1	0
975	Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial. Diabetes Therapy, 2022, 13, 161-173.	1.2	0
976	An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1461-1469.	1.8	9
977	SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality. Frontiers in Cardiovascular Medicine, 2021, 8, 791311.	1.1	6
978	Cardiorenal benefits of glucagon-like peptide-1 analogues vs. exendin-4 analogues in patients with type 2 diabetes: a meta-analysis based on cardiovascular outcome trials. European Journal of Preventive Cardiology, 2021, , .	0.8	1
979	Glycated hemoglobin as a surrogate for evaluating the effectiveness of drugs in diabetes mellitus trials: a systematic review and trial-level meta-analysis. International Journal of Technology Assessment in Health Care, 2022, 38, e12.	0.2	2

#	Article	IF	Citations
980	Comparative Cardio-Renal Outcomes of Type 2 Diabetes Patients Administered Glucagon-Like Peptide-1 Receptor Agonists: A Network Meta-Analysis. Frontiers in Pharmacology, 2021, 12, 759262.	1.6	2
981	Management of Hyperglycemia in Older Adults with Type 2 Diabetes. Drugs and Aging, 2022, 39, 39-58.	1.3	5
982	Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients. Cardiovascular Diabetology, 2021, 20, 235.	2.7	15
983	Kidney function assessment and endpoint ascertainment in clinical trials. European Heart Journal, 2022, 43, 1379-1400.	1.0	8
984	Opportunities of Antidiabetic Drugs in Cardiovascular Medicine. Hypertension, 2020, 76, 420-431.	1.3	6
986	Advances in Biological and Clinical Research of GLP-1 Receptor Agonists. Advances in Clinical Medicine, 2022, 12, 2979-2988.	0.0	0
987	Universal Clinician Device for improving risk prediction and management of patients with atrial fibrillation: an assumed benefit analysis. European Heart Journal Digital Health, 2022, 3, 181-194.	0.7	1
988	Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations. Journal of Diabetes, 2022, 14, 315-333.	0.8	4
989	Cardiovascular Events with Finerenone in CKD and Diabetes. New England Journal of Medicine, 2022, 386, e43.	13.9	3
990	Diabetes Medications and Cardiovascular Disease Prevention. Korean Journal of Family Practice, 2022, 12, 61-71.	0.1	0
991	Impact of Glucagon-Like Peptide 1 Receptor Agonists in Patients with Hemoglobin A1c of 9% or Greater. Journal of Pharmacy Practice, 2023, 36, 1125-1133.	0.5	0
992	Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients. Journal of Endocrinological Investigation, 2022, 45, 1587-1598.	1.8	10
993	Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3448-e3454.	1.8	2
994	New Diabetes Guidelines: Impact on Eligibility for Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Canada. Canadian Journal of Diabetes, 2022, 46, 691-698.	0.4	5
995	GuÃa ESC 2021 sobre la prevenciÃ³n de la enfermedad cardiovascular en la prÃ¡ctica clÃ¬nica. Revista Espanola De Cardiologia, 2022, 75, 429.e1-429.e104.	0.6	27
997	Semaglutide in type 2 diabetes with chronic kidney disease at high risk progressionâ€"real-world clinical practice. CKJ: Clinical Kidney Journal, 2022, 15, 1593-1600.	1.4	14
998	New Approaches to Diabetic Nephropathy from Bed to Bench. Biomedicines, 2022, 10, 876.	1.4	4
999	Effect of the Glucagon-Like Peptide-1 Receptor Agonists on Autonomic Function in Subjects with Diabetes: A Systematic Review and Meta-Analysis. Diabetes and Metabolism Journal, 2022, 46, 901-911.	1.8	7

#	Article	IF	Citations
1000	Position Paper on the Diagnosis and Treatment of Peripheral Arterial Disease (PAD) in People with Diabetes Mellitus. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, S127-S136.	0.6	1
1001	Any expectations from the more powerful dulaglutide?. Vnitrni Lekarstvi, 2022, 68, 124-126.	0.1	0
1002	Recent Advances on Drug Development and Emerging Therapeutic Agents Through Targeting Cellular Homeostasis for Ageing and Cardiovascular Disease. Frontiers in Aging, 2022, 3, .	1.2	4
1003	Metformin Protects against Diabetic Cardiomyopathy: An Association between Desminâ€“Sarcomere Injury and the iNOS/mTOR/TIMP-1 Fibrosis Axis. Biomedicines, 2022, 10, 984.	1.4	7
1005	Macrovascular Complications. Primary Care - Clinics in Office Practice, 2022, 49, 255-273.	0.7	2
1006	Trends in Use of High-Cost Antihyperglycemic Drugs Among US Adults with Type 2 Diabetes. Journal of General Internal Medicine, 2022, , 1.	1.3	0
1007	Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global <scp>DISCOVER</scp> study. Diabetes, Obesity and Metabolism, 2022, 24, 1734-1740.	2.2	0
1008	Healthcare Resource Utilization and Associated Costs in New Users of Empagliflozin versus DPP-4 Inhibitors and GLP-1 Agonists: A Comparative Analysis Based on Retrospective Real-World Data from German Sickness Funds. ClinicoEconomics and Outcomes Research, 2022, Volume 14, 319-332.	0.7	1
1009	Novel Drugs for Diabetes Also Have Dramatic Benefits on Hard Outcomes of Heart and Kidney Disease. Current Cardiology Reviews, 2022, 18, .	0.6	1
1010	Association between glucagonâ€like peptideâ€1 receptor agonists and biliaryâ€related diseases in patients with type 2 diabetes: a nationwide cohort study. Pharmacotherapy, 2022, , .	1.2	2
1011	Recent advances in the pharmacotherapeutic management of diabetic kidney disease. Expert Opinion on Pharmacotherapy, 2022, 23, 791-803.	0.9	5
1012	Pathophysiology, phenotypes and management of type 2 diabetes mellitus in Indian and Chinese populations. Nature Reviews Endocrinology, 2022, 18, 413-432.	4.3	62
1013	The timeâ€varying cardiovascular benefits of glucagonâ€like peptideâ€1 receptor agonist therapy in patients with type 2 diabetes mellitus: Evidence from large multinational trials. Diabetes, Obesity and Metabolism, 2022, 24, 1607-1616.	2.2	7
1014	Comparative cardiovascular effectiveness of glucagonâ€like peptideâ€1 receptor agonists versus sodiumâ€glucose cotransporterâ€2 inhibitors in patients with type 2 diabetes: A populationâ€based cohort study. Diabetes, Obesity and Metabolism, 2022, 24, 1623-1637.	2.2	9
1015	The Effects of Dipeptidyl Peptidase 4 Inhibitors on Renal Function in Patients with Type 2 Diabetes Mellitus. Journal of Clinical Medicine, 2022, 11, 2653.	1.0	2
1016	Effect of expanded dulaglutide weekly doses (3.0 mg and 4.5 mg) on cardiovascular disease risk factors in participants with type 2 diabetes at increased cardiovascular disease risk: a post hoc analysis of the AWARDâ€11 study. Diabetes, Obesity and Metabolism, 2022, , .	2.2	3
1017	Efficacy and safety outcomes of dulaglutide by baseline <scp>HbA1c</scp>: A post hoc analysis of the <scp>REWIND</scp> trial. Diabetes, Obesity and Metabolism, 2022, 24, 1753-1761.	2.2	2
1018	Polycystic ovary syndrome: a â€œrisk-enhancingâ€•factor for cardiovascular disease. Fertility and Sterility, 2022, 117, 924-935.	0.5	34

#	Article	IF	Citations
1019	Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials. BMC Endocrine Disorders, 2022, 22, 125.	0.9	10
1020	Effects of diet and antihyperglycemic drugs on erectile dysfunction: A systematic review. Andrology, 2023, 11, 282-294.	1.9	14
1021	Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6. Cardiovascular Diabetology, 2022, 21, 64.	2.7	4
1022	The use of glucagon-like-peptide-1 receptor agonist in the cardiology practice. Acta Cardiologica, 2023, 78, 552-564.	0.3	2
1023	Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia, 2022, 65, 1251-1261.	2.9	93
1024	Study Design and Baseline Characteristics of Patients with T2DM in the Post-marketing Safety Study of Dulaglutide in China (TRUST-CHN). Diabetes Therapy, 2022, , .	1.2	2
1025	The inhibitory effects of Dulaglutide on cellular senescence against high glucose in human retinal endothelial cells. Human Cell, 2022, 35, 995-1004.	1.2	4
1026	Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study). BMJ Open, 2022, 12, e056885.	0.8	2
1027	Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6. Stroke, 2022, 53, 2749-2757.	1.0	30
1031	Exposureâ€"Response Analysis of Cardiovascular Outcome Trials With Incretin-Based Therapies. Frontiers in Endocrinology, 2022, 13, .	1.5	3
1032	Glucose-Lowering Therapy beyond Insulin in Type 1 Diabetes: A Narrative Review on Existing Evidence from Randomized Controlled Trials and Clinical Perspective. Pharmaceutics, 2022, 14, 1180.	2.0	0
1033	Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs. Antioxidants, 2022, 11, 1060.	2.2	2
1035	Semaglutide treatment attenuates vessel remodelling in ApoEâ^'/â^' mice following vascular injury and blood flow perturbation. Atherosclerosis Plus, 2022, , .	0.3	1
1036	Real-World Prescription Patterns and Barriers Related to the Use of Sodium-Glucose Cotransporter 2 Inhibitors among Korean Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease. Diabetes and Metabolism Journal, 2022, 46, 701-712.	1.8	8
1037	Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care, 2022, 45, 1670-1690.	4.3	109
1038	Pharmacokinetic and pharmacodynamic studies of supaglutide in rats and monkeys. European Journal of Pharmaceutical Sciences, 2022, 175, 106218.	1.9	1
1039	A Novel Dual Incretin Agent, Tirzepatide (LY3298176), for the Treatment of Type 2 Diabetes Mellitus and Cardiometabolic Health. Journal of Cardiovascular Pharmacology, 2022, 80, 171-179.	0.8	4
1040	The effect of Dulaglutide on glycemic and weight control in patients with type 2 diabetes. Medicine and Pharmacy Reports, 0, , .	0.2	0

#	Article	IF	Citations
1041	Diabetes: how to manage chronic kidney disease. Drugs in Context, 0, 11, 1-10.	1.0	0
1042	Effect of glucagon-like peptide 1 receptor agonists on the renal protection in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes and Metabolism, 2022, 48, 101366.	1.4	6
1043	Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial. Diabetes Care, 2022, 45, 1592-1600.	4.3	11
1044	New Hypoglycemic Drugs: Combination Drugs and Targets Discovery. Frontiers in Pharmacology, 0, 13, .	1.6	7
1045	Expert consensus on personalized initiation of glucoseâ€lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease. Journal of Evidence-Based Medicine, 2022, 15, 168-179.	0.7	3
1046	Optimizing the Use of Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes: Executive Summary. Clinical Diabetes, 0, , .	1.2	1
1047	Hypertension and Type 2 Diabetesâ€"The Novel Treatment Possibilities. International Journal of Molecular Sciences, 2022, 23, 6500.	1.8	13
1048	Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice. Frontiers in Endocrinology, 0, 13, .	1.5	6
1049	Rethinking the role of pioglitazone in modern diabetology as a cardiorenoprotective agent. Meditsinskiy Sovet, 2022, , 10-21.	0.1	4
1050	Hypoglycaemic therapy in frail older people with type 2 diabetes mellitusâ€"a choice determined by metabolic phenotype. Aging Clinical and Experimental Research, 2022, 34, 1949-1967.	1.4	11
1053	Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias. Acta Cardiologica, 2023, 78, 519-524.	0.3	9
1055	Diabetes: how to manage cardiovascular risk in secondary prevention patients. Drugs in Context, 0, 11, 1-12.	1.0	1
1056	Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease. Journal of Diabetes Investigation, 2022, 13, 1472-1488.	1.1	2
1057	Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis. EClinicalMedicine, 2022, 50, 101510.	3.2	11
1058	Effectiveness and clinical benefits of new anti-diabetic drugs: A real life experience. Open Medicine (Poland), 2022, 17, 1203-1215.	0.6	5
1059	Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity. , 2022, 18, 43.		4
1060	Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes. , 2022, 18, 10.		12
1061	SEA 2022 standards for the comprehensive control of cardiovascular risk. ClÃnica E InvestigaciÃ³n En Arteriosclerosis (English Edition), 2022, 34, 130-179.	0.1	1

#	Article	IF	Citations
1062	Hypoglycemia Risk With SGLT2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists Versus Sulfonylureas Among Medicare Insured Adults With CKD in the United States. Kidney Medicine, 2022, 4, 100510.	1.0	9
1063	An Early Assessment of the Real-World Treatment Patterns of Type 2 Diabetes: A Comparison to the 2018 ADA/EASD Consensus Report Recommendations. Diabetes Therapy, 0, , .	1.2	1
1064	Are we there yet? Increasing use of cardioprotective antihyperglycemic agents in patients with T2D and CVD or CV risk in the United States. Current Medical Research and Opinion, 2022, 38, 1785-1795.	0.9	2
1065	Glycaemic Control in Patients Undergoing Percutaneous Coronary Intervention: What Is the Role for the Novel Antidiabetic Agents? A Comprehensive Review of Basic Science and Clinical Data. International Journal of Molecular Sciences, 2022, 23, 7261.	1.8	4
1066	New Therapeutic Options for Type 2 Diabetes Mellitus and Their Impact Against Ischemic Heart Disease. Frontiers in Physiology, 0, 13, .	1.3	0
1067	The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study. Cardiovascular Diabetology, 2022, 21, .	2.7	16
1068	A Retrospective Observational Study Examining the Generalizability of Glucagon-Like PeptideÂ1 Receptor Agonist Cardiovascular Outcome Trials to the Real-World Population with TypeÂ2 Diabetes in Spain: The REPRESENT Study. Advances in Therapy, 2022, 39, 3589-3601.	1.3	3
1071	Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?. Endocrinology and Metabolism, 2022, 37, 415-429.	1.3	3
1072	The role of Recent Pharmacotherapeutic Options on the Management of Treatment Resistant Type 2 Diabetes. Expert Opinion on Pharmacotherapy, 2022, 23, 1259-1271.	0.9	2
1074	Diagnosis and Management of Heart Disease. , 2022, , 139-172.		0
1075	New-Onset Atrial Fibrillation in Patients With Type 2 Diabetes Treated With Novel Glucose-Lowering Therapies. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2493-2499.	1.8	10
1076	The Effects of Adding Semaglutide to High Daily Dose Insulin Regimens in Patients With Type 2 Diabetes. Annals of Pharmacotherapy, 0, , 106002802211073.	0.9	0
1077	Therapy of Type 2 Diabetes. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, S80-S112.	0.6	5
1078	Part Three: A Brief Primer of Non-Insulin Treatments for Type 2 Diabetes Mellitus in Older People. , 2022, 37, 251-259.		1
1080	Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials). American Journal of Cardiology, 2022, 178, 11-17.	0.7	3
1081	Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology, 0, 13, .	1.5	19
1082	Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes â€“ A systematic review and meta-analysis. Journal of Diabetes and Its Complications, 2022, 36, 108255.	1.2	18
1083	Nephroprotective Effects of Semaglutide as Mono- and Combination Treatment with Lisinopril in a Mouse Model of Hypertension-Accelerated Diabetic Kidney Disease. Biomedicines, 2022, 10, 1661.	1.4	5

#	Article	IF	Citations
1084	Obesity and chronic kidney disease: A current review. Obesity Science and Practice, 2023, 9, 61-74.	1.0	15
1085	Effect of glucagon-like peptide-1 (GLP-1) analogues on epicardial adipose tissue: A meta-analysis. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102562.	1.8	7
1087	Type 2 diabetics followed up by family physicians: Treatment sequences and changes over time in weight and glycated hemoglobin. Primary Care Diabetes, 2022, 16, 670-676.	0.9	1
1088	An investigation of physicians' prescribing behaviors related to antidiabetic agents for Type 2 diabetes mellitus patients and associated factors in Taiwan. Current Medical Research and Opinion, 0, , 1-19.	0.9	0
1089	Progress in the management of patients with diabetes and chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2022, 31, 456-463.	1.0	1
1090	Clinical CharacteristicsÂof Inpatients With New-Onset Diabetes Mellitus in Eastern China: Based on Novel Clustering Analysis. Frontiers in Endocrinology, 0, 13, .	1.5	3
1091	GLP-1 Receptor Agonists in the Treatment of Patients with Type 2 Diabetes and Chronic Kidney Disease. Kidney and Dialysis, 2022, 2, 386-398.	0.5	0
1093	The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice. Therapeutic Advances in Endocrinology and Metabolism, 2022, 13, 204201882211124.	1.4	9
1094	Do Glucagonlike Peptide-1 Receptor Agonist and Sodium-glucose Co-transporter 2 Inhibitor Prescriptions in Germany Reflect Recommendations for Type 2 Diabetes with Cardiovascular Disease of the ADA/EASD Consensus Report?. Experimental and Clinical Endocrinology and Diabetes, 2023, 131, 153-161.	0.6	1
1095	Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: A systematic review and meta-analysis. Frontiers in Endocrinology, 0, 13, .	1.5	6
1096	2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults. Canadian Journal of Cardiology, 2022, 38, 1153-1167.	0.8	17
1097	Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China. Diabetes Therapy, 0, , .	1.2	3
1098	Gut immune cellsâ€"A novel therapeutical target for cardiovascular disease?. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	1
1100	Role of therapeutic inertia in glycemic control according to individualized objectives in a cohort of patients with type 2 diabetes. Results from CONCARDIA2. EndocrinologÃa Diabetes Y NutriciÃ³n (English) Tj ETQq1 1 0.784314 rgBT		
1101	Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective. Diabetes, Obesity and Metabolism, 2023, 25, 3-17.	2.2	36
1102	American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Planâ€"2022 Update. Endocrine Practice, 2022, 28, 923-1049.	1.1	146
1103	An approach to insulin tapering and discontinuation after glucagon-like peptide-1 receptor agonist initiation. American Journal of Health-System Pharmacy, 0, , .	0.5	0
1104	Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes. Cardiovascular Diabetology, 2022, 21, .	2.7	18

#	Article	IF	Citations
1105	Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment. Diabetes, Obesity and Metabolism, 2022, 24, 2297-2308.	2.2	14
1106	Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists. Cardiovascular Research, 2023, 119, 886-904.	1.8	6
1107	Anti-Diabetic Therapy, Heart Failure and Oxidative Stress: An Update. Journal of Clinical Medicine, 2022, 11, 4660.	1.0	6
1108	A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes. Cardiovascular Diabetology, 2022, 21, .	2.7	6
1109	Highlighting the Role of Obesity and Insulin Resistance in Type 1 Diabetes and Its Associated Cardiometabolic Complications. Current Obesity Reports, 2022, 11, 180-202.	3.5	9
1110	The role of GLP-1 receptor agonists in managing type 2 diabetes. Cleveland Clinic Journal of Medicine, 2022, 89, 457-464.	0.6	8
1111	Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study. Cardiovascular Diabetology, 2022, 21, .	2.7	12
1112	Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes. Cardiovascular Diabetology, 2022, 21, .	2.7	3
1113	The Effectiveness of Sodium-Glucose Cotransporter 2ÂInhibitors and Glucagon-like Peptide-1 Receptor AgonistsÂon Cardiorenal Outcomes: Systematic Review andÂMeta-analysis. Canadian Journal of Cardiology, 2022, 38, 1201-1210.	0.8	12
1114	Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study. Journal of Clinical Medicine, 2022, 11, 4938.	1.0	9
1116	Medication Deprescribing Among Patients With Type 2 Diabetes: A Qualitative Case Series of Lifestyle Medicine Practitioner Protocols. Clinical Diabetes, 2023, 41, 163-176.	1.2	6
1117	Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs. Kidney International Reports, 2022, 7, 2345-2355.	0.4	3
1118	DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits. Military Medical Research, 2022, 9, .	1.9	4
1119	Glucose control independent mechanisms involved in the cardiovascular benefits of glucagon-like peptide-1 receptor agonists. Biomedicine and Pharmacotherapy, 2022, 153, 113517.	2.5	6
1120	Questions and answers on the use of aspirin for primary prevention of cardiovascular disease in diabetes. Diabetes Research and Clinical Practice, 2022, 191, 110043.	1.1	1
1121	Translating results from the cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists into clinical practice: Recommendations from a Eastern and Southern Europe diabetes expert group. International Journal of Cardiology, 2022, 365, 8-18.	0.8	18
1122	Beyond HbA1c cardiovascular protection in type 2 diabetes mellitus. Journal of Endocrinology Metabolism and Diabetes of South Africa, 2023, 28, 7-13.	0.4	1
1123	Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study. Diabetes Therapy, 2022, 13, 1921-1932.	1.2	11

#	Article	IF	Citations
1124	The role of coronary artery calcium in allocating pharmacotherapy for primary prevention of cardiovascular disease: The ABCs of CAC. Clinical Cardiology, 2022, 45, 1107-1113.	0.7	5
1125	Emerging roles of Glucagon like peptide-1 in the management of autoimmune diseases and diabetes-associated comorbidities. , 2022, 239, 108270.		9
1126	Herz und Diabetes. Springer Reference Medizin, 2022, , 1-14.	0.0	0
1127	Glucagon Like Peptide-1: More than Glucose Control and Weight Reduction. SSRN Electronic Journal, 0, , .	0.4	0
1128	Noncardiovascular-derived therapeutic peptidomimetics in cardiovascular disease. , 2022, , 615-654.		0
1129	A Health Technology Assessment Based on Chinese Guidelines: Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Type 2 Diabetes Complicated with Cardiovascular Disease. Therapeutics and Clinical Risk Management, 0, Volume 18, 889-900.	0.9	0
1130	Single-center Evaluation of Safety & Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Solid Organ Transplantation. Progress in Transplantation, 2022, 32, 357-362.	0.4	6
1131	Dulaglutide and a Composite Outcome Reflecting Atherosclerosis in the REWIND Trial: A Post Hoc Analysis. Diabetes Care, 2022, 45, e146-e147.	4.3	0
1132	Meta-analysis of the association between new hypoglycemic agents and digestive diseases. Medicine (United States), 2022, 101, e30072.	0.4	2
1133	Tratamiento farmacolÃ³gico del paciente que vive con diabetes mellitus tipo 2. CES Medicina, 2022, 36, 81-105.	0.1	0
1134	Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2022, 65, 1925-1966.	2.9	273
1135	Glycemia Reduction in Type 2 Diabetes â€" Microvascular and Cardiovascular Outcomes. New England Journal of Medicine, 2022, 387, 1075-1088.	13.9	62
1136	The potential of glucagon-like peptide-1 receptor agonists in heart failure. Frontiers in Physiology, 0, 13, .	1.3	3
1137	Type 2 diabetes and cardiovascular disease: risk reduction and early intervention. Postgraduate Medicine, 2023, 135, 2-12.	0.9	5
1138	Glucagonâ€like peptide 1 receptor agonists in heart failure: the need for a rewind. European Journal of Heart Failure, 2022, 24, 1813-1815.	2.9	3
1139	Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2022, 45, 2753-2786.	4.3	435
1140	Recent Advances in the Emerging Therapeutic Strategies for Diabetic Kidney Diseases. International Journal of Molecular Sciences, 2022, 23, 10882.	1.8	9
1141	Semaglutida en enfermedad renal diabÃ©tica: Experiencia en dos programas de salud renal en Colombia. Revista Colombiana De EndocrinologÃa, Diabetes & Metabolismo, 2022, 9, .	0.1	0

#	Article	IF	Citations
1142	Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a postâ€hoc analysis from the REWIND randomized trial. European Journal of Heart Failure, 2022, 24, 1805-1812.	2.9	12
1143	Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodiumâ€glucose cotransporterâ€2 (<scp>SGLT2)</scp> inhibitors compared with glucagonâ€like peptideâ€1 receptor agonists (<scp>GLP</scp>â€1<scp>RAs)</scp>: A pooled analysis of type 2 diabetes trials. Diabetes, Obesity and Metabolism, 2023, 25, 166-176.	2.2	2
1144	The long-term cost-effectiveness of once-weekly semaglutide 1Âmg vs. dulaglutide 3Âmg and 4.5Âmg in the UK. European Journal of Health Economics, 0, , .	1.4	2
1145	Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options. Biomedicines, 2022, 10, 2274.	1.4	22
1146	The societal impact of early intensified treatment in patients with type 2Âdiabetes mellitus. Journal of Comparative Effectiveness Research, 2022, 11, 1185-1199.	0.6	1
1147	Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study. Frontiers in Pharmacology, 0, 13, .	1.6	2
1148	Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the <scp>FIGHT</scp> trial. Diabetes, Obesity and Metabolism, 2023, 25, 189-197.	2.2	14
1149	Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular Diabetology, 2022, 21, .	2.7	79
1151	Use of Glucose-Lowering Agents in Diabetes and CKD. Kidney International Reports, 2022, 7, 2589-2607.	0.4	7
1152	Letter regarding the article â€˜Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a <scp>postâ€hoc</scp> analysis from the <scp>REWIND</scp> randomized trial. European Journal of Heart Failure, 2022, 24, 2207-2207.	2.9	0
1153	Diabetes and cardiovascular risk according to sex: An overview of epidemiological data from the early Framingham reports to the cardiovascular outcomes trials. Annales D'Endocrinologie, 2023, 84, 57-68.	0.6	2
1154	Costâ€utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China. Diabetes, Obesity and Metabolism, 2023, 25, 387-397.	2.2	2
1155	Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care, 2022, 45, 3075-3090.	4.3	161
1156	First-Line Therapy for Type 2 Diabetes With Sodiumâ€“Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Annals of Internal Medicine, 2022, 175, 1392-1400.	2.0	32
1157	Longâ€Term Activation of Glucagonâ€like peptideâ€1 receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes. Journal of the American Heart Association, 2022, 11, .	1.6	6
1158	Diabetes management in chronic kidney disease: aÂconsensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International, 2022, 102, 974-989.	2.6	65
1159	Effects of dulaglutide on endothelial progenitor cells and arterial elasticity in patients with type 2 diabetes mellitus. Cardiovascular Diabetology, 2022, 21, .	2.7	9
1160	The effect of allopurinol on cardiovascular outcomes in patients with type 2 diabetes: a systematic review. Hormones, 2022, 21, 599-610.	0.9	2

#	Article	IF	Citations
1161	Cardiovascular disease management in Australian adults with type 2 diabetes: insights from the <scp>CAPTURE</scp> study. Internal Medicine Journal, 2023, 53, 1796-1805.	0.5	1
1162	Using modern risk engines and machine learning/artificial intelligence to predict diabetes complications: A focus on the BRAVO model. Journal of Diabetes and Its Complications, 2022, 36, 108316.	1.2	6
1163	An Experimental Study of the Neuroprotective Effect of Sodiumâ€“Glucose Cotransporter Type 2 Inhibitors. Journal of Evolutionary Biochemistry and Physiology, 2022, 58, 1540-1553.	0.2	1
1164	Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLYÂ® study. Cardiovascular Diabetology, 2022, 21, .	2.7	1
1165	Assessment of Additional Risk Factors for Cardiovascular Disease and Awareness Among Adult Patients With Diabetes Mellitus: A Cross-Sectional Study From Northern Sri Lanka. Cureus, 2022, , .	0.2	1
1166	Nephroprotective Properties of the Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) Receptor Agonists. Biomedicines, 2022, 10, 2586.	1.4	6
1167	Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study. Frontiers in Endocrinology, 0, 13, .	1.5	1
1171	Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis. Frontiers in Pharmacology, 0, 13, .	1.6	10
1172	Efficacy and safety of dulaglutide compared with the first-line hypoglycemic drugs in Asian patients with type 2 diabetes: a systematic review and meta-analysis. Scientific Reports, 2022, 12, .	1.6	3
1173	Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States. Kidney Medicine, 2023, 5, 100564.	1.0	10
1174	Incretin and insulin signaling as novel therapeutic targets for Alzheimerâ€™s and Parkinsonâ€™s disease. Molecular Psychiatry, 2023, 28, 217-229.	4.1	21
1175	Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology, 0, 13, .	1.5	21
1176	The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study. Frontiers in Public Health, 0, 10, .	1.3	7
1177	Coordinating Cardiology clinics randomized trial of interventions to improve outcomes (COORDINATE) â€“ Diabetes: rationale and design. American Heart Journal, 2023, 256, 2-12.	1.2	3
1179	An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes. Medicina (Lithuania), 2022, 58, 1475.	0.8	11
1180	Weight loss between glucagonâ€like peptideâ€1 receptor agonists and bariatric surgery in adults with obesity: A systematic review and metaâ€analysis. Obesity, 2022, 30, 2111-2121.	1.5	12
1181	KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International, 2022, 102, S1-S127.	2.6	246
1182	Cardiorenal disease management in type 2 diabetes: An expert consensus. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2022, 16, 102661.	1.8	1

#	Article	IF	Citations
1183	Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. Expert Opinion on Pharmacotherapy, 2022, 23, 1957-1974.	0.9	0
1184	Therapeutic mechanism and clinical application of Chinese herbal medicine against diabetic kidney disease. Frontiers in Pharmacology, 0, 13, .	1.6	4
1185	Pharmacotherapy of type 2 diabetes: An update and future directions. Metabolism: Clinical and Experimental, 2022, 137, 155332.	1.5	35
1186	Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: A systematic review and meta-analysis. EClinicalMedicine, 2022, 54, 101697.	3.2	13
1187	The treatment of diabetes in advanced liver disease: change of a paradigm. Annals of Hepatology, 2023, 28, 100772.	0.6	4
1188	Multidisciplinary Approach to Management and Care of Patients with Type 2 Diabetes Mellitus. European Medical Journal Diabetes, 0, , 73-81.	4.0	5
1189	Effects of GLP-1 Receptor Agonists on Cardiovascular Events and Their Clinical Positioning. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 2458-2464.	0.0	0
1190	Comparison of Glucose Lowering Efficacy of Human GLP-1 Agonist in Taiwan Type 2 Diabetes Patients after Switching from DPP-4 Inhibitor Use or Non-Use. Journal of Personalized Medicine, 2022, 12, 1915.	1.1	2
1191	Alogliptin and Heart Failure Outcomes in Patients With Type 2 Diabetes. Journal of Pharmacy Practice, 2024, 37, 410-414.	0.5	1
1192	The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes. Diabetes, Obesity and Metabolism, 2023, 25, 639-648.	2.2	3
1193	Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2022 update. Cmaj, 2022, 194, E1460-E1480.	0.9	5
1194	Metaâ€analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes. ESC Heart Failure, 2023, 10, 552-567.	1.4	3
1195	Atherosclerotic Cardiovascular Disease or Heart Failure: First Cardiovascular Event in Adults With Prediabetes and Diabetes. Journal of Cardiac Failure, 2023, 29, 246-254.	0.7	4
1196	Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity. Obesity Facts, 2023, 16, 149-163.	1.6	4
1197	Deficits and Disparities in Early Uptake of Glucagon-Like Peptide 1 Receptor Agonists and SGLT2i Among Medicare-Insured Adults Following a New Diagnosis of Cardiovascular Disease or Heart Failure. Diabetes Care, 2023, 46, 65-74.	4.3	8
1198	Safety and effectiveness of dulaglutide 0.75â€‰mg in Japanese patients with type 2 diabetes in realâ€world clinical practice: 36 month postâ€marketing observational study. Journal of Diabetes Investigation, 0, , .	1.1	0
1199	Potential Roles of Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs) in Nondiabetic Populations. Cardiovascular Therapeutics, 2022, 2022, 1-9.	1.1	9
1200	Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Cardiovascular Diabetology, 2022, 21, .	2.7	16

#	Article	IF	Citations
1201	OnkodiabetolÃ³gia II.. Orvosi Hetilap, 2022, 163, 1575-1584.	0.1	0
1202	A cohort study of circulating progenitor cells after ST-segment elevation and non-ST segment elevation myocardial infarction in non-diabetic and diabetic patients. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0
1203	Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis. Diabetologia, 2023, 66, 642-656.	2.9	7
1204	Glucocentric Drugs in Cardiovascular Disease Protection and Heart Failure. Methodist DeBakey Cardiovascular Journal, 2022, 18, 40-53.	0.5	0
1205	Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Diseaseâ€"Current Evidence. Journal of Cardiovascular Pharmacology and Therapeutics, 2022, 27, 10742842211463.	1.0	15
1206	Effect of new glucose-lowering drugs on stroke in patients with type 2 diabetes: A systematic review and Meta-analysis. Journal of Diabetes and Its Complications, 2023, 37, 108362.	1.2	5
1207	Corrigendum to â€œMechanisms and pharmacotherapy of hypertension associated with type 2 diabetesâ€• [Biochem. Pharmacol. 206 (2022) 115304]. Biochemical Pharmacology, 2023, 207, 115349.	2.0	0
1208	Safety Pharmacology Evaluation of Biopharmaceuticals. , 2022, , 1-16.		0
1209	The GLP-1 receptor agonists: whatâ€™s all the (cardiovascular) hype about?. South African General Practitioner, 2022, 3, 118-120.	0.0	0
1210	Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis. Frontiers in Pharmacology, 0, 13, .	1.6	10
1212	Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2022;46:630-9). Diabetes and Metabolism Journal, 2022, 46, 953-955.	1.8	0
1213	Transitioning to GLP-1 RAs and SGLT2 Inhibitors as the First Choice for Managing Cardiometabolic Risk in Type 2 Diabetes. Current Atherosclerosis Reports, 2022, 24, 925-937.	2.0	2
1214	Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?. International Journal of Molecular Sciences, 2022, 23, 14598.	1.8	5
1215	Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice. Nature Reviews Endocrinology, 2023, 19, 151-163.	4.3	21
1216	Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China. Diabetes Therapy, 2023, 14, 93-107.	1.2	2
1217	Mechanisms of GLPâ€'1 Receptor Agonists on the Cardio-Renal Protective Effects. Japanese Journal of Clinical Pharmacology and Therapeutics, 2022, 53, 249-262.	0.1	0
1218	Nueva evidencia en el tratamiento de la enfermedad renal diabÃ©tica: Â¿quÃ© aporta la finerenona?. Revista Colombiana De NefrologÃa, 2022, 9, .	0.1	0
1219	Recommendations for Early and Comprehensive Management of Type 2 Diabetes and Its Related Cardio-Renal Complications. Diabetes Therapy, 0, , .	1.2	0

#	Article	IF	Citations
1220	Clinical Pharmacy Specialist Collaborative Management and Prescription of Diabetes Medications with Cardiovascular Benefit. Journal of Pharmacy Practice, 2024, 37, 435-441.	0.5	0
1221	GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. Circulation, 2022, 146, 1882-1894.	1.6	58
1222	Tirzepatide and prevention of chronic kidney disease. CKJ: Clinical Kidney Journal, 2023, 16, 797-808.	1.4	10
1223	Series: Cardiovascular outcome trials for diabetes drugs.. British Journal of Diabetes, 2022, 22, 105-111.	0.1	0
1224	Managing Diabetes. Physician Assistant Clinics, 2022, , .	0.1	0
1225	The Impact of Pharmacist Intervention to Improve Medication Access for Patients with Diabetes. Journal of the American Pharmacists Association: JAPhA, 2022, , .	0.7	0
1226	Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials. Diabetology and Metabolic Syndrome, 2022, 14, .	1.2	4
1227	Assessing the Effects of Modern Renoprotective Agents in Preventing Progression of Renal Composite Outcomes in Patients with Type 2 Diabetes: A Network Meta-analysis. Diabetes Therapy, 0, , .	1.2	0
1228	Gender disparities in time-to-initiation of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: a Danish nationwide cohort study. Cardiovascular Diabetology, 2022, 21, .	2.7	5
1229	Prevention of cardiorenal damage: importance of albuminuria. European Heart Journal, 2023, 44, 1112-1123.	1.0	12
1230	Implementing the new NICE guidelines for type 2 diabetes (NG28): Focusing beyond HbA1c targets and clinically phenotyping patients to the appropriate second-line agent. British Journal of Diabetes, 2022, 22, 87-94.	0.1	0
1231	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetesâ€”2023. Diabetes Care, 2023, 46, S158-S190.	4.3	156
1232	Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin. Pharmaceuticals, 2022, 15, 1569.	1.7	0
1233	Integrating Coronary Atherosclerosis Burden and Progression with Coronary Artery Disease Risk Factors to Guide Therapeutic Decision Making. American Journal of Medicine, 2023, 136, 260-269.e7.	0.6	10
1234	Risk of stroke and retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: An eight RCTs meta-analysis. Frontiers in Endocrinology, 0, 13, .	1.5	9
1235	Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data. Frontiers in Endocrinology, 0, 13, .	1.5	0
1236	Caring for Patients With Diabetes in Stroke Neurology. Stroke, 2023, 54, 894-904.	1.0	5
1237	The place of Glucagon-like 1 peptide receptor agonists (GLP-1RAs) in the new NICE guidelines â€“ what is going on?. British Journal of Diabetes, 2022, 22, 69-71.	0.1	0

#	Article	IF	Citations
1238	Statistical power for MACE and individual secondary endpoints in cardiovascular outcomes trials for type 2 diabetes: a systematic review. Scientific Reports, 2022, 12, .	1.6	0
1239	Nationwide cardiovascular risk categorization: applying the European Society of Cardiology guidelines to the Swedish National Diabetes Register. European Journal of Preventive Cardiology, 2023, 30, 546-551.	0.8	2
1240	Diabetes Mellitus at an Elderly Age. Experimental and Clinical Endocrinology and Diabetes, 0, , .	0.6	1
1241	GLP-1R Signaling and Functional Molecules in Incretin Therapy. Molecules, 2023, 28, 751.	1.7	7
1242	Diabetes and Stroke: What Are the Connections?. Journal of Stroke, 2023, 25, 26-38.	1.4	21
1243	New Antidiabetic Agents: Relevance to Cardiovascular Outcomes. Updates in Hypertension and Cardiovascular Protection, 2023, , 337-349.	0.1	0
1244	Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: A review. Vascular Medicine, 2023, 28, 62-76.	0.8	4
1245	Recent Pharmacological Options in Type 2 Diabetes and Synergic Mechanism in Cardiovascular Disease. International Journal of Molecular Sciences, 2023, 24, 1646.	1.8	18
1246	Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs. Metabolites, 2023, 13, 87.	1.3	6
1247	Atherosclerotic Cardiovascular Disease Prevention in the Older Adult: Part 2. Contemporary Cardiology, 2023, , 67-138.	0.0	0
1248	Realâ€world weightâ€loss effectiveness of glucagonâ€like peptideâ€1 agonists among patients with type 2 diabetes: A retrospective cohort study. Obesity, 2023, 31, 537-544.	1.5	5
1249	Early intervention and intensive management of patients with diabetes, cardiorenal, and metabolic diseases. Journal of Diabetes and Its Complications, 2023, 37, 108389.	1.2	7
1250	The prevalence of cardiovascular disease in adults with type 2 diabetes mellitus in Saudi Arabia - CAPTURE study. Journal of King Abdulaziz University, Islamic Economics, 2023, 44, 57-66.	0.5	5
1251	Effect of Glucagon-like Peptide-1 Receptor Agonists on Prognosis of Heart Failure and Cardiac Function: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Clinical Therapeutics, 2023, 45, 17-30.	1.1	6
1252	Control of Blood Glucose and Cardiovascular Risk Profile. Updates in Hypertension and Cardiovascular Protection, 2023, , 451-469.	0.1	0
1253	Ligne directrice C-CHANGE pour lâ€™harmonisation des lignes directrices nationales de prÃ©vention et de prise en charge des maladies cardiovasculaires en contexte de soins primaires au Canada: mise Ã jour 2022. Cmaj, 2023, 195, E21-E42.	0.9	1
1254	Novel Therapeutics for Type 2 Diabetes, Obesity, and Heart Failure. Journal of Cardiopulmonary Rehabilitation and Prevention, 2023, 43, 1-7.	1.2	3
1255	Dual GIP/GLP-1 receptor agonists: New advances for treating type-2 diabetes. Annales D'Endocrinologie, 2023, 84, 316-321.	0.6	15

#	Article	IF	Citations
1256	Impact of Glucagon-like peptide 1 receptor agonists on peripheral arterial disease in people with diabetes mellitus: A narrative review. Journal of Diabetes and Its Complications, 2023, 37, 108390.	1.2	6
1257	Clinical spotlight intervention to accelerate translation of evidence-based practices in primary care. BMJ Open Quality, 2022, 11, e002032.	0.4	1
1258	Use of sodiumâ€“glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists according to the 2019 ESC guidelines and the 2019 ADA/EASD consensus report in a national population of patients with type 2 diabetes. European Journal of Preventive Cardiology, 2023, 30, 634-643.	0.8	7
1260	Selective somatostatin receptor 5 inhibition improves hepatic insulin sensitivity. Pharmacology Research and Perspectives, 2023, 11, .	1.1	3
1261	The Common Single Cause of Chronic Multi-Hormonal Resistance in Oxidative Stress. Antioxidants, 2023, 12, 75.	2.2	1
1262	Preparing for Colonoscopy in People with Diabetes: A Review with Suggestions for Clinical Practice. Journal of the Canadian Association of Gastroenterology, 2023, 6, 26-36.	0.1	2
1263	Research Progress in Treatment of Diabetic Proteinuria. Advances in Clinical Medicine, 2023, 13, 1252-1260.	0.0	0
1265	Tirzepatide for Weight Loss: Can Medical Therapy â€œOutweighâ€•Bariatric Surgery?. Cardiology in Review, 2023, 31, 278-283.	0.6	2
1266	Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis. PLoS ONE, 2023, 18, e0278685.	1.1	9
1267	Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023. , 2023, 5, 100056.		11
1268	Safety and tolerability of semaglutide across the <scp>SUSTAIN</scp> and <scp>PIONEER</scp> phase <scp>IIIa</scp> clinical trial programmes. Diabetes, Obesity and Metabolism, 2023, 25, 1385-1397.	2.2	7
1269	The Safety and Efficacy of GLP-1 Receptor Agonists in Heart Failure Patients: A Systematic Review and Meta-Analysis. Current Problems in Cardiology, 2023, 48, 101602.	1.1	4
1271	Evaluation and Management of Patients with Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. Diabetes and Metabolism Journal, 2023, 47, 10-26.	1.8	4
1273	Medical therapy. , 2023, , 353-361.		0
1274	Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial. Frontiers in Endocrinology, 0, 14, .	1.5	4
1275	Evaluation and Management of Patients With Diabetes and Heart Failure: A Korean Diabetes Association and Korean Society of Heart Failure Consensus Statement. International Journal of Heart Failure, 2023, 5, 1.	0.9	2
1276	Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity. Frontiers in Endocrinology, 0, 14, .	1.5	7
1277	Emerging Therapy for Diabetic Cardiomyopathy: From Molecular Mechanism to Clinical Practice. Biomedicines, 2023, 11, 662.	1.4	3

#	Article	IF	Citations
1278	Tirzepatide: A Novel Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide 1 Receptor Agonist for the Treatment of Type 2 Diabetes: The First Twincretin. Clinical Diabetes, 2023, 41, 367-377.	1.2	2
1279	The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: A mini-review of the potential mechanisms. Current Opinion in Pharmacology, 2023, 69, 102355.	1.7	7
1280	Research progress on the effects of novel hypoglycemic drugs in diabetes combined with myocardial ischemia/reperfusion injury. Ageing Research Reviews, 2023, 86, 101884.	5.0	3
1281	Health Care Provider Prescribing Habits and Barriers to Use of New Type 2 Diabetes Medications: A Single-System Survey Study. Clinical Diabetes, 0, , .	1.2	0
1282	Updates of precision medicine in type 2 diabetes. , 2023, 1, .		0
1283	Recent developments in adjunct therapies for type 1 diabetes. Expert Opinion on Investigational Drugs, 2022, 31, 1311-1320.	1.9	3
1284	N6-methylation of RNA-bound adenosine regulator HNRNPC promotes vascular endothelial dysfunction in type 2 diabetes mellitus by activating the PSEN1-mediated Notch pathway. Diabetes Research and Clinical Practice, 2023, 197, 110261.	1.1	5
1285	Therapeutic inertia related to the injectable glucagonâ€like peptideâ€1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in <scp>UK</scp> primary care. Diabetes, Obesity and Metabolism, 2023, 25, 1331-1340.	2.2	1
1286	Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment. Journal of Managed Care & Specialty Pharmacy, 2023, 29, 139-150.	0.5	0
1287	GLPâ^'1 receptor agonists for the treatment of obesity: Role as a promising approach. Frontiers in Endocrinology, 0, 14, .	1.5	20
1288	Gender differences in cardiovascular risk, treatment, and outcomes: a post hoc analysis from the REWIND trial. Scandinavian Cardiovascular Journal, 2023, 57, .	0.4	2
1289	<scp>Glucagonâ€like</scp> peptideâ€1 receptor analogues in renal transplant recipients with diabetes: Medium term follow of patients from a single UK centre. Diabetic Medicine, 2023, 40, .	1.2	1
1290	Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo. Kidney International, 2023, 103, 772-781.	2.6	16
1291	Should SGLT2 inhibitors be prescribed in all diabetic type 2 patients?. Archives of Medical Science, 2023, 19, 528-531.	0.4	0
1292	Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies. BMC Medicine, 2023, 21, .	2.3	8
1293	Impact of chronic GLP-1 RA and SGLT-2I therapy on in-hospital outcome of diabetic patients with acute myocardial infarction. Cardiovascular Diabetology, 2023, 22, .	2.7	3
1294	Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond. Endocrinology and Metabolism, 2023, 38, 25-33.	1.3	4
1295	The postprandial actions of GLP-1 receptor agonists: The missing link for cardiovascular and kidney protection in type 2 diabetes. Cell Metabolism, 2023, 35, 253-273.	7.2	16

#	Article	IF	Citations
1296	Unexploited potential of risk factor treatment in patients with atherosclerotic cardiovascular disease. European Journal of Preventive Cardiology, 2023, 30, 601-610.	0.8	7
1297	Patterns of new glucagonâ€like peptideâ€1 receptor agonist use in patients with type 2 diabetes during 2014â€“2019 from a US database: prescriber and patient characteristics. Journal of Diabetes, 2023, 15, 190-195.	0.8	2
1298	GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 1806-1812.	1.8	7
1299	Improvement of Left Ventricular Global Longitudinal Strain after 6-Month Therapy with GLP-1RAs Semaglutide and Dulaglutide in Type 2 Diabetes Mellitus: A Pilot Study. Journal of Clinical Medicine, 2023, 12, 1586.	1.0	3
1300	Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial. Circulation, 2023, 147, 1004-1013.	1.6	7
1302	Effect of dulaglutide in promoting abstinence during smokingÂcessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial. EClinicalMedicine, 2023, 57, 101865.	3.2	4
1303	Analysis of the Value of SGLT2i Combined with GLP-1RAs in Cardiovascular Benefit of Elderly T2DM Patients. Advances in Clinical Medicine, 2023, 13, 2736-2743.	0.0	0
1304	GLP-1ÂRAs in Spain: A Short Narrative Review of Their Use in Real Clinical Practice. Advances in Therapy, 2023, 40, 1418-1429.	1.3	1
1305	Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists. American Journal of Preventive Cardiology, 2023, 13, 100477.	1.3	2
1306	Effect of Intensive Glycemic Control on Myocardial Infarction Outcome in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Journal of Diabetes Research, 2023, 2023, 1-11.	1.0	0
1307	Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes. Cardiology Research, 2023, 14, 12-21.	0.5	6
1308	Effects of incretin-based therapeutic agents including tirzepatide on renal outcomes in patients with type 2 diabetes: A systemic review and meta-analysis. Metabolism Open, 2023, 17, 100236.	1.4	6
1309	Vitreous hemorrhage during GLP-1 receptor agonist treatment. Journal of the American Pharmacists Association: JAPhA, 2023, 63, 976-979.	0.7	1
1310	Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagonâ€like peptideâ€1 receptor agonist: A retrospective analysis of the Diabetes Prospective Followâ€Up Registry. Diabetes, Obesity and Metabolism, 2023, 25, 1813-1822.	2.2	5
1311	Stroke Prevention and Treatment in People With Type 2 Diabetes: Is There a Role for GLP-1 (Glucagon-Like Peptide-1) Analogues?. Stroke, 2023, 54, 1441-1451.	1.0	2
1312	Effects of glucagonâ€like peptideâ€1 receptor agonists on major coronary events in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2023, 25, 53-63.	2.2	4
1313	Use and Interchange of Incretin Mimetics in the Treatment of Metabolic Diseases: A Narrative Review. Clinical Therapeutics, 2023, 45, 248-261.	1.1	2
1314	Exendin-4 attenuates atherosclerosis progression via controlling hematopoietic stem/progenitor cell proliferation. Journal of Molecular Cell Biology, 0, , .	1.5	0

#	Article	IF	Citations
1315	Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial. Journal of Diabetes Investigation, 2023, 14, 774-781.	1.1	3
1316	Safety and cardiometabolic efficacy of novel antidiabetic drugs. Expert Opinion on Drug Safety, 2023, 22, 119-124.	1.0	1
1317	Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects. Expert Opinion on Biological Therapy, 2023, 23, 727-735.	1.4	0
1318	Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes. Cardiovascular Diabetology, 2023, 22, .	2.7	3
1319	The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes. Cardiovascular Diabetology, 2023, 22, .	2.7	0
1320	Biomarker Changes Associated With Both Dulaglutide and Cardiovascular Events in the REWIND Randomized Controlled Trial: A Nested Case-Control Post Hoc Analysis. Diabetes Care, 2023, 46, 1046-1051.	4.3	2
1321	Paradigm sift of the medical care in diabetes. Nihon Ika Daigaku Igakkai Zasshi, 2023, 19, 32-41.	0.0	0
1322	Demystifying the Progression of Retinopathy with Glucagon-Like Peptide-1 Receptor Agonists: Facts, Evidence, and Misperceptions. , 2022, 1, 53.		0
1323	Glucagon-Like Peptide-1 Receptor Agonist Protects Against Diabetic Cardiomyopathy by Modulating microRNA-29b-3p/SLMAP. Drug Design, Development and Therapy, 0, Volume 17, 791-806.	2.0	1
1324	Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study. Biomedicines, 2023, 11, 869.	1.4	3
1325	Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes. World Journal of Diabetes, 0, 14, 188-197.	1.3	1
1326	CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes. Cardiovascular Diabetology, 2023, 22, .	2.7	4
1327	The cardiovascular and renal effects of glucagon-like peptide 1 receptor agonists in patients with advanced diabetic kidney disease. Cardiovascular Diabetology, 2023, 22, .	2.7	3
1328	Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2023, 18, 602-612.	2.2	12
1329	The Fat Kidney. Current Obesity Reports, 0, , .	3.5	0
1331	Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials. Cardiovascular Diabetology, 2023, 22, .	2.7	4
1332	An Investigation on the Efficacy of Glucagon-Like Peptide 1 Receptor Agonists Drugs in Reducing Urine Albumin-to-Creatinine Ratio in Patients With Type 2 Diabetes: A Potential Treatment for Diabetic Nephropathy. Cureus, 2023, , .	0.2	0
1333	Recent Trials on the Cardioprotective Effects of New Generation Anti-diabetic and Lipid-Lowering Agents. Frontiers in Clinical Drug Research Diabetes and Obesity, 2023, , 117-167.	0.1	0

#	Article	IF	Citations
1334	Effects of oral semaglutide on cardiovascular outcomes in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of <scp>SOUL</scp>, a randomized trial. Diabetes, Obesity and Metabolism, 2023, 25, 1932-1941.	2.2	22
1335	Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovascular Diabetology, 2023, 22, .	2.7	16
1336	Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study. Cardiovascular Diabetology, 2023, 22, .	2.7	4
1337	General versus central adiposity as risk factors for cardiovascular-related outcomes in a high-risk population with type 2 diabetes: a post hoc analysis of the REWIND trial. Cardiovascular Diabetology, 2023, 22, .	2.7	2
1338	Comprehensive Insulin and Noninsulin Injectable Diabetes Medication Resource: Update. ADCES in Practice, 2023, 11, 30-35.	0.2	1
1339	Lower-limb peripheral arterial disease and amputations in people with diabetes: Risk factors, prognostic value and management. Presse Medicale, 2023, 52, 104164.	0.8	3
1340	Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nature Reviews Cardiology, 2023, 20, 463-474.	6.1	46
1341	Effect of glucagon-like peptide-1 receptor agonists administration during coronary artery bypass grafting: a systematic review and meta-analysis of randomized control trials. Future Cardiology, 0, , .	0.5	1
1342	Glucagon-like peptide-1 receptor agonists: role in the prevention and treatment of diabetes-related cardiovascular complications. , 2023, , 365-396.		0
1343	Management of diabetic kidney disease: where do we stand?: A narrative review. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Overlock	0.4	3
1344	Early Insight Into the Retrospective Data of a Case Series on Type 2 Diabetes Mellitus on Alternate-Day Dosing of Oral Semaglutide: Utopia or Reality?. Cureus, 2023, , .	0.2	2
1345	Embedding guidelines into clinical practice. Practical Diabetes, 2023, 40, 28.	0.1	0
1346	Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023). Swiss Medical Weekly, 2023, 153, 40060.	0.8	5
1347	Efficacy and safety of <scp>onceâ€weekly</scp> efpeglenatide in people with suboptimally controlled type 2 diabetes: The <scp>AMPLITUDEâ€Ð</scp>, <scp>AMPLITUDEâ€Ł</scp> and <scp>AMPLITUDEâ€Š</scp> randomized controlled trials. Diabetes, Obesity and Metabolism, 2023, 25, 2084-2095.	2.2	2
1348	Glucagon-like peptide 1 receptor agonists in end-staged kidney disease and kidney transplantation: A narrative review. Nutrition, Metabolism and Cardiovascular Diseases, 2023, 33, 1111-1120.	1.1	3
1349	Diabetic Kidney Disease. Medical Clinics of North America, 2023, 107, 689-705.	1.1	12
1350	Semaglutide-eye-catching results. World Journal of Diabetes, 0, 14, 424-434.	1.3	2
1352	The Effects of Cardioprotective Antidiabetic Therapy on Microbiota in Patients with Type 2 Diabetes Mellitusâ€"A Systematic Review. International Journal of Molecular Sciences, 2023, 24, 7184.	1.8	4

#	Article	IF	Citations
1353	Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting GLP-1/Fc fusion protein after a single ascending dose in Chinese healthy subjects. European Journal of Pharmaceutical Sciences, 2023, 185, 106448.	1.9	1
1354	Anti-Diabetic Therapy and Heart Failure: Recent Advances in Clinical Evidence and Molecular Mechanism. Life, 2023, 13, 1024.	1.1	1
1355	Pharmacological management of youth with type 2 diabetes and diabetic kidney disease: a comprehensive review of current treatments and future directions. Expert Opinion on Pharmacotherapy, 2023, 24, 913-924.	0.9	0
1356	Tirzepatide: Clinical review of the â€œtwincretinâ€•injectable. American Journal of Health-System Pharmacy, 2023, 80, 879-888.	0.5	2
1357	Recent advances in the treatment of patients with obesity and chronic kidney disease. Annals of Medicine, 2023, 55, .	1.5	4
1379	Liraglutide and Cardiovascular Outcomes in Diabetes (LEADER)-2016. , 2023, , 91-94.		0
1384	Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis. International Journal of Obesity, 2023, 47, 677-685.	1.6	10
1385	SGLT2 Inhibitors and GLP1 Antagonists on Diabetes and Cardiovascular Disease. Contemporary Cardiology, 2023, , 923-968.	0.0	0
1386	Diabetes and Stroke: The Role of Glucose Regulation. , 2023, , 837-855.		0
1387	Incretin Therapies: Current Use and Emerging Possibilities. , 2023, , 565-580.		0
1400	The Wedding Bells Sound Really Good! iGlarLixi Fixed-Ratio Combination in the Treatment of TypeÂ2 Diabetes: A Narrative Review. Advances in Therapy, 0, , .	1.3	0
1403	New IFSO/ASMBS Indications for Metabolic and Bariatric Surgery? Yes, After Failure of Best Nonsurgical Therapy. Obesity Surgery, 0, , .	1.1	1
1415	Tailoring the Treatment of Type 2 Diabetes Mellitus to the Individual. Contemporary Cardiology, 2023, , 1043-1070.	0.0	0
1453	Clinical Outcomes with GLP-1 Receptor Agonists in Patients with Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Drugs, 2023, 83, 1293-1307.	4.9	2
1460	Incretins and cardiovascular disease: to the heart of type 2 diabetes?. Diabetologia, 2023, 66, 1820-1831.	2.9	3
1466	Effects of newer-generation anti-diabetics on diabetic retinopathy: a critical review. Graefe's Archive for Clinical and Experimental Ophthalmology, 2024, 262, 717-752.	1.0	2
1469	A Systematic Approach to Treating Early Metabolic Disease and Prediabetes. Diabetes Therapy, 2023, 14, 1595-1607.	1.2	0
1480	Beginning and Managing Underlying Comorbidities. , 2023, , 49-63.		0

#	Article	IF	Citations
1487	Pharmacotherapy of Obesity and Metabolic Syndrome. , 2023, , 1-25.		0
1493	From a glycocentric approach in the patient with type 2 diabetes mellitus to a multi-organ prevention treatment and a decrease in the neuro-nephro-cardiovascular outcomes.. , 0, , .		0
1494	Diabetes Mellitus:. , 2024, , 439-455.		0
1496	Challenging Clinical Perspectives in TypeÂ2 Diabetes with Tirzepatide, a First-in-Class Twincretin. Diabetes Therapy, 2023, 14, 1997-2014.	1.2	1
1545	Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes. Current Atherosclerosis Reports, 0, , .	2.0	0
1548	Herz und Diabetes. Springer Reference Medizin, 2023, , 205-218.	0.0	0
1587	Pharmacotherapy of Obesity and Metabolic Syndrome. , 2023, , 713-737.		0
1591	Treat Obesity to Treat Type 2 Diabetes Mellitus. Diabetes Therapy, 2024, 15, 611-622.	1.2	0